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Protein biotherapeutics, especially monoclonal antibodies (mAbs), have been on the rise due to 
their high efficacy, potency, and low toxicity. They are mainly used for the treatment of cancer, 
autoimmune diseases, infectious diseases, and organ transplantation. While mAbs are well-
tolerated by patients and have fewer adverse effects, their stability can be challenged by physical 
and chemical degradation. Hence, they are formulated with buffers and other excipients such as 
polysorbate 80 (PS80), which help to maintain the pH of the formulation and prevent aggregation, 
respectively. However, when the drug product is exposed to light, heat, or contains metal 
impurities, they are likely to undergo degradation. Some of the reactive amino acids of the proteins 
such as Trp, Tyr, His, Met, and Cys residues are more prone to photooxidation. Thus, we have 
investigated the effect of both UV and visible light on peptides, and proteins and further looked 
into the role of protein- and buffer-derived radicals on degradation of PS80.  
We explored the role of methionine sulfur cation, generated by photosensitization of 4-
carboxybenzophenone in the Met-Xn-His-containing peptides (n = 0 - 2), a common sequence 
present in the biotherapeutics such as mAb and human parathyroid hormone. Here, we report on 
the formation of novel photo-oxidation products and cross-links between Met oxidation product(s) 
and a neighboring histidine residue. Mechanisms for the formation of these products will be 
proposed. Specifically, the formation of cross-links is hypothesized to involve photo-oxidation of 
Met to an aspartate semialdehyde, followed by reaction with the imidazole side chain of His, and 
elimination of water.  
When a full mAbZ (mAb obtained from AstraZeneca) was exposed to visible light, discoloration 
of the solution was observed. The chromophoric product responsible for the color change was 
identified using a model Trp-containing compound, N-acetyl-L-tryptophan amide (NATA). The 
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product was identified as NATA-33, a conjugated product formed after loss of 33 Da from NATA, 
by mass spectrometry and NMR. The mAbZ formulation contains polysorbate 80 (PS80) that has 
unsaturated fatty acids such as oleic acid and linoleic acid. Hence, we address the question of how 
protein-derived radicals may affect the composition of PS80. Isobaric products of PS80 were 
identified by means of mass spectrometry, suggesting cis/trans isomerization of unsaturated fatty 
acids of PS80. This mechanism was confirmed by the analysis of isolated fatty acids, 
demonstrating, e.g., the conversion of oleic acid to elaidic acid. Another commonly used excipient 
in mAb biotherapeutics is citrate buffer. In the presence of metal impurities such as iron, citrate 
buffer and iron can generate citrate-derived degradants such as carbon dioxide radical anion after 
exposure to UV-A light. Such radical anion can donate an electron to a disulfide bond and form a 
thiyl radical, which can also induce cis/trans isomerization of unsaturated fatty acids of PS80. 
Therefore, photo-induced radicals and radical ions may lead to cross-linking of amino acids, color 
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Chapter 1: Introduction 
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1.1. Monoclonal Antibody as Therapeutics 
Murine monoclonal antibody (mAb) was first produced in 1975 by César Milstein and Georges 
Köhler by using groundbreaking hybridoma technology, which opened a door for antibodies to be 
used as therapeutics.1-2 After a decade, in 1986 the first murine mAb, Orthoclone OKT3, was 
approved by the US Food and Drug Administration (FDA).3 In the early development of murine 
mAbs, immunogenicity and short half-lives of these mAbs were of concern due to the presence of 
anti-murine antibody in patients.4 This response was significantly reduced through the 
implementation of technologies such as chimeric, humanized, and full human mAbs. Since then, 
mAbs have emerged as an important class of drugs because of their potency, low toxicity, and high 
efficacy. Furthermore, mAbs are well-tolerated by patients, have fewer adverse effects, and are 
highly specific in comparison to small molecules.5 Thus, 79 FDA approved mAbs are in the market 
for the treatment of cancers, autoimmune diseases, infectious diseases, and organ 
transplantations.4, 6 Whilst mAbs have become less immunogenic with the transition away from 
mouse mAb sequences, degradation due to intrinsic and extrinsic factors remains.  
Various factors such as protein formulations, container closure, manufacturing processes, and 
environmental factors (light and temperature) need to be considered to improve the stability of 
mAbs.7 Moreover, factors such as metal contaminants, pH, and ionic strength can also influence 
the stability of drugs.7-10 As a result of temperature and light stress and/or the presence of metal 
contaminants, mAbs can experience oxidation,11-14 aggregation,15-16 fragmentation,17-18 cross-link 
formation,19-20 and color change.16, 21-22 These degradation products may induce product 
immunogenicity risking patient’s health. To mitigate the degradation of mAbs during long-term 
storage conditions, a robust formulation should be implemented that can be corroborated with 
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forced-stability studies. Formulation for each mAb should be addressed as a “case by case” basis 
because of the structural differences in the complementary determining regions (CDRs) and 
glycosylation.23  
1.2. Structure of mAbs 
Most of the marketed mAbs are γ-immunoglobins (IgG) isotypes and are mainly comprised of 
IgG1, IgG2, and IgG4. These mAbs are tetrameric glycoproteins with molecular weights (MW) of 
approximately 150 kDa.24-25 As shown in Fig. 1, they consist of two identical heavy chains (HC), 
each with a MW of about 50 kDa, and two identical light chains (LC), each with a MW of about 
25 kDa. These roughly Y-shaped proteins consist of three HC constant domains (CH1, CH2, and 
CH3), one HC variable domain (VH), one LC constant domain (CL), and one LC variable domain 
(VL). The CH2 and CH3 domains are part of the fragment crystallizable (Fc), which binds to cell 
surface receptors including the Fcγ receptors and the neonatal Fc receptor (FcRn). The VL-VH and 
CL-CH1 domains make up the antigen binding fragment (Fab) region containing the highly variable 
complimentary determining region (CDR) responsible for binding to target antigen. Due to these 
complexities in antibody structure, identification of degradation hotspots has become a key area 
of research. 
Certain structural motifs have been identified that are susceptible to degradation throughout the 
stages of mAb production.26-28 For instance, the sequences Gly-Asn or Asn-Gly are more prone to 
deamidation. Yang et al. changed two degradation hotspots, LC-Asn30 and HC-Asp102 into LC-
Gln30 and HC-Glu102, which decreased the rate of deamidation and isomerization, and retained 
the biological activity.29 Kumar et al. has carried out single point (V44K, E59S, E59T and E59Y) 
and double mutations (V44KE59S, V44KE59T and V44KE59Y) in the light chain of mAb1 that 
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improved the biological activity, protein solubility, and viscosity of the protein.26 Such mutations 
can also disrupt aggregation and oxidation prone hotspots.  
1.3. Routes of administration of mAbs 
Traditionally, mAbs are administered via the intravenous route in the hospital settings. mAbs are 
infused based on the patient’s weight, so the diluted mAbs, though more stable, take several hours 
of infusion time.30 This requires trained personnel to prepare, administer, and monitor the drug 
product (DP) and the lengthy process also compromises patient’s compliance. As such, other 
routes of administration such as intramuscular (IM) and subcutaneous (SC) injections are being 
explored. SC injection requires administration of highly concentrated mAb solutions (≥100 
mg/ml) in small volumes. For SC injections, pre-filled syringes, pens and auto-injectors are used, 
enabling patients to use them at home and reducing injection time to minutes. Thus, SC 
administration is becoming increasingly popular due to its user convenience, better therapy 
compliance, and economic impacts.31 Whilst SC injections have many advantages over IV 
injections, concerns of reduced volume, back-pressure, and pain at the site of injection remain. 
To overcome such concerns, mAbs such as rituximab and trastuzumab took advantage of an 
excipient such as recombinant hyaluronidase (rHuPH20)5, 32-33 and were approved for tumor 
therapy. rHuPH20 is an enzyme that temporarily degrades hyaluronan at the injection site, 
facilitating delivery of ~5-10 ml via SC injection.  
The stability of a highly concentrated DP in an SC formulation is crucial for its success; however, 
the highly concentrated mAb makes it challenging because of protein-protein interactions, which 
lead to high viscosity and aggregation. Self-association of the protein may be mainly attributed to 
electrostatic interactions,34 in particular Fab-Fab interactions.35 By changing the charged residues 
in the CDR of a mAb, Yadav et al. were able to reduce its viscosity.36 Additionally, when exposed 
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to UV and visible light, heat, and/or metal contaminants, highly concentrated mAbs are reported 
to aggregate or undergo color change due to greater protein-protein interactions and reduced 
volume.16, 21-22  
1.4. Degradation of antibodies 
The stability of mAbs can be compromised during manufacturing and administration, mainly via 
interfacial stress, mechanical stress, light exposure, and metal-catalyzed oxidation (MCO). These 
stresses and reactions may degrade mAbs, causing physical and chemical instability.8-9, 37 Physical 
instability is defined as structural changes of proteins without formation or breakage of the 
chemical bonds. For example, physical instability of the protein may be caused by hydrophobic 
interactions between two or more molecules, leading to protein aggregation because of shear forces 
and cavitation-induced spikes in pressure and temperature.8, 38 Alternatively, chemical instability 
is defined by change in covalent bonds, i.e. hydrolysis of the existing bonds or the formation of 
new bonds. Thus, deamidation, β-elimination, fragmentation, aggregation, oxidation, and cross-
link formation fall under chemical instability. Physical and chemical instabilities are interrelated 
as one can influence the other. For instance, aggregation in proteins can also occur via chemical 
instability by disulfide scrambling and cross-links between various amino acids. 
Oxidation occurs mainly via (i) peroxides, (ii) metal-catalyzed oxidation (MCO), and (iii) light 
exposure. Peroxides may be introduced into the drug substance (DS) as contaminants from 
excipients. Iron can be present in the solution as contaminant from manufacturing and storage 
containers, and excipients, which promotes MCO and can generates ROS such as the hydroxyl 
radical (•OH) by Fenton reaction.39 Peroxides and other oxidants generated by MCO and light 
exposure may react with numerous amino acids including: methionine (Met), cysteine (Cys), 
tryptophan (Trp), histidine (His), tyrosine (Tyr), and phenylalanine (Phe).13, 40-41 These ROS can 
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result in the generation of oxidation products such as methionine sulfoxide (MetO) that can, for 
example, modify the biological activity of a protein and alter the binding affinity of IgGs.42-43 
MCO has also been reported to play a role in the hydrolysis between Met and His residues in 
human parathyroid hormone and IgG1.17-18 Therefore, it is important to carefully monitor 
contaminants that may be introduced into the formulation to avoid degradation of the proteins.  
The exposure of the DP to light during manufacturing, storage, or administration can result in 
degradation, altering the protein irreversibly. The aromatic residues of proteins can undergo 
photoexcitation that may result in either type I or type II photooxidation (Scheme 1).44 In the type 
I mechanism, light is directly absorbed by chromophores such as aromatic amino acids (e.g. Trp, 
Tyr), giving an excited triplet state.45-47 This is followed by the transfer of an electron to a suitable 
acceptor, such as molecular oxygen (O2) or disulfide bonds, leading to the formation of radical 
cations (e.g. Trp radical cation) and radical anions; O2 will form superoxide48 or disulfide will 
form a disulfide radical anion, which exists in equilibrium with thiolate and thiyl radical.14, 49-50 
Thiyl radicals can undergo a cascade of reactions such as disulfide scrambling,51-52 thioether 
formation,53 abstraction of either an electron, hydrogen, or both from other amino acids,50, 54 and 
involvement in cis/trans isomerization.55-56  The latter topic is discussed in detail in Chapters 4 and 
5. On the other hand, the formation of a Trp radical cation can lead to the loss of the side chain of 
Trp57-58 and Tyr59 after UV light exposure. For instance, a Trp radical cation can abstract an 
electron from Tyr, forming a Tyr radical cation, which can then eliminate a protonated quinone 
methide. Other amino acids may also undergo light-induced oxidation, including Met, which 
primarily degrades into MetO. Photosensitizers such as 4-caboxybenzophenone (4-CB) have 
widely been used to study the oxidation of Met via the type I mechanism, which gives a sulfur 
radical cation (Met>S•+).60 We have employed this technique to generate Met>S•+, which led to 
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the identification of novel cross-links between Met oxidation product(s) and a His residue, 
discussed in Chapter 2. 
In the type II mechanism, energy is transferred from an excited triplet state to O2, generating singlet 
oxygen (1O2). This reactive oxygen species can react with Met and His, forming MetO11-12 and 
peroxide derivatives of His, respectively.61 In addition, 1O2 may react with Trp, generating 
photoproducts such as N-formyl kynurenine (NFK) and kynurenine (Kyn). These photoproducts 
can further act as photosensitizers, resulting in the degradation of proteins upon exposure to UV-
A and visible light.62-66 Therefore, the International Conference on Harmonization (ICH) has 
provided guidelines for drug product exposure to UV-A and visible light stresses, which are 
outlined in section 1.5 and 1.6. 
1.5. ICH Q1B guideline and photostability testing of biotherapeutics 
According to the ICH guidelines for photostability testing of DS(s) and DP(s) (Q1B), “light testing 
should be an integral part of stress testing”.67 For forced degradation and confirmatory testing, 
ICH requires the DS and DP to be tested using light sources with output similar to D65/ID65. The 
ICH guideline defines D65 and ID65 as follows:  “D65 is the internationally recognized standard 
for outdoor daylight as defined in The International Standards Organization (ISO) 10977 (1993). 
ID65 is the equivalent indoor indirect daylight standard.” D65 and ID65 can be accomplished by 
using artificial daylight fluorescent lamps, xenon lamps, or metal halide lamps. However, if cool 
white fluorescent lamps are used, it has to be accompanied by near UV lamps. All of these light 
source options should emit no less than 1.2 million lux hours of visible light and no less than 200 
Watt hour per square meters (W.h/m2) of integrated near UV light. In addition, a dark control 
wrapped in aluminum should be tested alongside the authentic sample in the same environment. 
Dark control samples can also indicate the effect of heat generated on DP during light exposure.  
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1.6. Case studies of highly concentrated mAbs degraded by UV-A and visible light 
When Qi et al. exposed a mAb (100 mg/ml formulated in histidine buffer, sorbitol and PS80 at pH 
5.5) to the light intensity recommended by ICH Q1B guideline, it underwent significant physical 
and chemical changes depicted by covalent aggregates, fragmentation, oxidation of Met, His, and 
Trp, and deamidation of Asn.16 After light exposure, the colorless mAb solution turned yellow, a 
result which was also observed in our study (discussed in Chapter 3) on highly concentrated mAb 
after exposure to visible light. Additionally, in the same study by Qi et al., a significant loss in 
biological activity of the mAb was observed due to Trp94 oxidation and Asn93 deamidation in the 
CDR region. Another study on 100 mg/ml mAb (MEDI-493) (in 10 mM His and 1.6 mM Gly 
buffer, pH 6.0) by Wei et al. also showed oxidation of Met and Trp after exposure to light emitting 
wavelengths between 300-700 nm for up to 7 days.68 However, one single Trp 105 residing in the 
CDR of the heavy chain was responsible for the loss of binding and biological activity. These two 
Trp residues are solvent-exposed, which explains their readily oxidizable nature. Apart from Trp, 
Met and His residues also undergo oxidation and may negatively impact the efficacy of the drug.42  
Commonly, the light exposure experienced by DS and DP is far less harsh than those outlined in 
the ICH Q1B guideline.22, 69-70 Sreedhara et al.22 have done an extensive internal survey in normal 
laboratories and GMP processing areas and found a small UV-A light source emitting from 350 to 
400 nm with an irradiance ranging from 0.05 to 0.3 W/m2. Areas that used fluorescent lamps with 
plastic canopies, however, emitted wavelengths above 400 nm (commonly termed as ambient and 
mild light conditions). This indicates DS and DP may not see such extreme conditions mentioned 
in the ICH Q1B guideline.22 In the same study, under ambient light, mAb1 showed a site-specific 
oxidation of Trp resulting in potency loss and mAb2 (at 100 mg/ml) showed higher aggregation 
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and a color change of the solution; however, mAb3-5 were not impacted by ambient and mild light 
exposure.  
Similarly, the study by Qi et al. 16 concluded that the mAb underwent oxidation (of Trp and Met), 
deamidation, fragmentation, and aggregation formation during light exposure according to the ICH 
Q1B guideline, but was stable under ambient light conditions. Because ambient light may still 
contain a UV quotient, it is ambiguous which wavelengths cause the degradation of mAbs. Du et 
al.71 gave some insights into which part of the visible light is responsible for the color change of a 
mAb formulation and degradation of the mAb. The visible light was divided into multiple color 
spectra by using either colored filters or by using blue and red LED lamps. The mAbs exposed to 
blue light, filtered from visible light, and emitted from blue LED lamps displayed a brown color 
with maximum absorbance at 450 nm.  Additionally, these mAb solutions displayed an increase 
in high molecular weight species and charge variant species. If possible, while handling highly 
photosensitive mAbs, such filters should be used to protect the proteins from degrading. It has also 
been suggested to fill the head space of the vials with N2 to protect the DS and DP from rapid 
degradation.72  
The ICH Q1B guideline does not specify the light exposed during drug preparation and patient 
administration; however, some DP requires pharmacy preparation and long hours of administration 
time, where the DP is further exposed to light. As shown by Du et al. certain wavelengths of visible 
light can degrade the DP and impose concerns for the drug’s efficacy and safety.71, 73 Therefore, 
the effect of light on mAbs highly depends on the photosensitivity of mAbs under study and light 
exposure time. The exposure to light during drug preparation and administration should also be 
considered when labelling the DP with “protect from light”. Moreover, providing detailed 
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instructions on protecting the DP from light and including protective sleeves as part of the product 
kit will ensure the protection of the drug.73   
Apart from the Active Pharmaceutical Ingredient (API), excipients added to the final formulations 
can also undergo physical and chemical changes when exposed to light. For example, polysorbate, 
a commonly used surfactant to protect biotherapeutics, is susceptible to degradation forming 
peroxides, formic acid, formaldehyde, hydrogen peroxide, etc. when exposed to light.74 Likewise, 
His buffer, a commonly used buffer, is also photosensitive. His degradation can form products that 
are photosensitizers, which can further oxidize other amino acid residues such as Met and Trp.  
Monoclonal antibodies formulated in His buffer are shown to suffer Trp oxidation in the CDR 
region, leading to reduced binding affinity for target proteins.75-76 Other excipients, such as Met 
and the Trp-derivative N-acetyl tryptophan (NAT), are used as antioxidants in the final DP 
formulation to reduce or prevent oxidation of proteins.77 However, the oxidation products of NAT 
are also photosensitizers and should be carefully monitored as they can further oxidize proteins.78 
Our study on another Trp-containing compound, N-acetyl-L-tryptophan amide (NATA), also 
revealed oxidation upon exposure to visible light giving products such as NFK, Kyn, OH-Trp and 
other chromophoric products, which is discussed in Chapter 3.  
1.7. Use of excipients for stabilizing mAbs 
Since the production and administration of mAbs requires many steps, keeping them stable is 
important not just to meet the critical quality attributes but also for the safety and efficacy of the 
drug.8 Thus, formulation conditions should be optimized to achieve a longer shelf life by 
minimizing both physical and chemical instabilities. Excipients such as buffers, surfactants, salts, 
antioxidants, and chelators are chosen for an ideal formulation condition to lower viscosity, 
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aggregation rate, oxidation, and other unwanted reactions. A library of generally regarded as safe 
(GRAS) excipients can be used for initial screening to avoid extra regulatory requirements.79  
Buffers are used to maintain the pH and stability of the drug solution. Detailed reviews regarding 
the role of buffers on protein stability are provided by Zbacnik et al.80 and Ugwu et al.81 The 
commonly used buffers for mAbs include His, phosphate, acetate, and citrate,82-85 where most of 
the concentrated mAbs are formulated in His buffer. Because most antibodies are formulated 
between pH 5.0 to 7.0, the use of His buffer is logical as its pKa is at 6.0. His buffer is also shown 
to decrease the viscosity of the high-concentration mAbs86 and inhibit aggregation of a mAb.75 
Despite its advantages, His can be affected by heat87 and light,88-89 so the DP has to be monitored 
carefully.  
Another commonly used buffer, citrate buffer has four distinct pKas at 3.13, 4.76, 5.80, and 6.40,90 
making it suitable for protein formulation across a large range of pHs.80 Some mAbs are shown to 
be more stable in citrate buffer via ligand binding. For example, Harinarayan et al. have shown  
binding of citrate buffer to the Fab region resulted in greater stability.91 Citrate, on the other hand, 
is also known to degrade or form adducts, resulting in acetonation of proteins92 or citrate can add 
to serine and threonine residues as adducts.93 The citrate-phosphate formulation of Humira® was 
changed in pre-filled syringes and pen injectors due to pain at injection site associated with 
citrate.94 In addition, our study discussed in Chapter 5 and a study by Subelzu et al.95 indicated a 
role of citrate in generating ROS via the photo-Fenton reaction, which can degrade amino acids 
and surfactants 
Excipients such as Met and Trp are used as sacrificial antioxidants, which maintain the stability of 
the protein by reacting with ROS instead of the amino acids in the protein. Other amino acids such 
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as His, Arg, and Lys are also added especially to highly concentrated mAb formulations to reduce 
viscosity and aggregation. These amino acids work either by interaction with aromatic acids or by 
electrostatic interaction.96 Likewise, salts are added to the formulation to maintain the ionic 
strength and surfactants such as polysorbates and poloxamers are added to reduce the aggregation 
of protein via surface interfaces. However, one has to monitor the quality of a neat surfactant as it 
may contain peroxides, which can degrade proteins. Furthermore, surfactants can undergo 
oxidation in presence of heat, light, and metal contaminants.74 They can also undergo hydrolysis 
in presence of host cell proteins, which are co-purified with desired proteins,97-100 forming 
unwanted particles in the DP formulations.  
1.8. Overview of this dissertation 
In this dissertation, the photo-degradation of model peptides, mAb, and surfactants are explored 
upon exposure to either UV or visible light. Both amino acid residues and surfactants, which are 
used to protect biotherapeutic proteins, are susceptible to degradation. The ingredients in the final 
formulation, such as mAb and surfactants, can have negative effect on each other. For example, 
the degradants of surfactants such as peroxides and aldehydes can oxidize reactive amino acids 
(Met and His) and react with Lys and Arg to form a Schiff base, respectively. In addition, free 
fatty acids generated from hydrolysis of ester bonds of polysorbate can form particles in the 
formulation raising concerns for patient safety. On the other hand, protein- (and citrate-) derived 
radical ions can generate ROS or thiyl radicals. These radicals can degrade surfactants or convert 
cis isomer of unsaturated fatty acids of PS80 to trans isomer,56 as presented in Chapters 4 and 5.  
The role of sulfur radical cations, specifically, on cross-link formation in the Met-Xn-His (n = 0-
2) sequence of model peptides is presented in Chapter 2. Finally, the formation of a chromophoric 
product in mAbZ formulations after exposure to visible light is discussed in Chapter 3. For these 
13 
 
studies RP-HPLC, HPLC-MS/MS, NMR, Raman spectroscopy, and FTIR were used to identify 
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 Chapter 2: One-electron photo-oxidation of Met-Xn-






Protein oxidation can target any amino acid depending on the oxidant; however, the aromatic 
(tryptophan, tyrosine, phenylalanine, and histidine) and sulfur-containing amino acids (cysteine 
(Cys), and methionine (Met)) are generally more susceptible to oxidation.1-3 In particular, the 
oxidation of Met to Met sulfoxide (MetO) can have consequences for protein stability, structure 
and biological activity.4 For example, upon Met oxidation to MetO calmodulin undergoes 
structural changes, which destabilize the protein.5-6 In another case, the oxidation of Met in actin 
reduced actin polymerization.4, 7-13 Met oxidation also affects the interactions of Met with 
tryptophan (Trp),14-15 lysine (Lys),16 and histidine (His).17 In biological systems, methionine 
sulfoxide reductase (Msr) isoforms are present to reduce MetO back to Met.18-19 However, the 
enzymatic reduction of MetO to Met is not possible in biotherapeutics, which are usually 
formulated for long time storage. Therefore, Met oxidation in biotherapeutics is carefully 
monitored. One issue of concern is the oxidation of Met residues in monoclonal antibodies , which 
can affect binding to the neonatal fragment crystallizable receptor (FcRn), leading to a decrease in 
receptor binding and potentially affecting the pharmacokinetics of the antibodies. 17, 20-21 
Met oxidation can occur through one or two-electron processes. The one-electron oxidation usually 
involves  a strong one-electron oxidant such as a hydroxyl radical (HO•),22-26 or an alkoxyl radical 
(RO•),27 even to a certain extent peroxynitrite, ONOO-.28-30 One-electron transfer from Met yields 
a Met sulfur radical cation (Met>S•+), which can form a 2 centers – 3 electrons (2c-3e) bond with 
a nearby heteroatom (oxygen, nitrogen, sulfur); such 2c-3e bonds were identified by their 
absorption spectra during time-resolved pulse radiolysis or flash photolysis experiments.31-32 On 
the other hand, the two-electron oxidation of Met can be achieved with hydrogen peroxide 




on the Fenton oxidation via [FeII(EDTA)]2-/H2O2 of parathyroid hormone 1-34 (PTH (1-34)) and 
a monoclonal antibody suggest that the intermediary generation of peptide and protein  Met>S•+ 
can lead to the hydrolysis of the peptide bond C-terminal of Met>S•+ specifically in the 
subsequence -Met-His-.24-25 In the proposed mechanism,24-25  the His residue served to bind an 
[FeII(EDTA)]2- complex to promote generation of an oxidant in the immediate vicinity of Met.  
The experiments described in the current chapter were undertaken in order to evaluate whether the 
generation of Met>S•+ in the absence of [FeII(EDTA)]2- would lead to hydrolysis of C-terminal of 
Met>S•+. For this purpose, we subjected Met-His-containing peptides to one-electron photo-
oxidation by triplet 4-cabrboxybenzophenone (*4-CB) according to the reactions 1 and 2.  
 
Earlier studies have elucidated reaction of *4-CB with Met and Met-containing peptides, where 
the additive quantum yield for the generation of Met>S•+ via reaction (2) was on the order of  0.08-
0.27.34-35 Importantly, upon one-electron photo-oxidation of the Met-Xn-His (n = 0-2) sequences 
subjected to photo-oxidation in the current chapter we did not observe subsequent hydrolysis 
indicating the formation of Met>S•+ in the absence of [FeII(EDTA)]2- was not sufficient for 
hydrolysis.  
However, the generation of Met>S•+ in our peptide sequence resulted in the formation of a series 
of (novel) photoproducts including covalent cross-link, possibly related to carbon-centered radical 




links is of great significance for protein oxidation during conditions of oxidative stress and 
aging.36-42 In addition cross-link formation is stability concern for the formulation and  
 
administration of protein biotherapeutics, where cross-links correlate with the loss of biological 
activity and the formation of aggregates and particles, which may be immunogenic.43-46 
Frequently, the mechanisms and structures of cross-links in protein biotherapeutics are unknown, 
and the current chapter adds some mechanistic insight into cross-link formation relevant for the 
semaphorin-6A and monoclonal antibodies and , which contain at least one, and some cases more 
than one Met-His subsequence in their structure.47-49 
2.2. Materials and Methods 
2.2.1.  Materials 
The model peptide M1 and LPLAHAL (A1) were purchased either from GenScript (Piscataway, 
NJ), or was synthesized in-house. All other model peptides, LPLM(13C5)HAL (M2), 
LPLMH(15N3)AL (M3), LPLMGHAL (M4), and LPLMGGHAL (M5) were synthesized in-house. 
All amino acids for peptide synthesis were from Gyros Protein Technologies AB (Tucson, AZ). 
The Fmoc stable isotope-labeled Met and His residues were purchased from Cambridge Isotope 
laboratories Inc (Tewksbury, MA). Triisopropylsilane (TIPS), trifluoroacetic acid (TFA), 4-CB, 
Girard’s reagent T (GRT), N-ethylmaleimide (NEM), and sodium borohydride (NaBH4) were from 
Sigma-Aldrich (St. Louis, MO) at the highest commercially available grade. Acetonitrile (ACN), 





(Hampton, NH).  The ultra-pure quality water (dH2O) (18.2 MΩ) was produced fresh daily by a 
WaterPro PS Polishing System (Labconco, Kansas City, MO). 
2.2.2. Synthesis of model peptides and purification 
Model peptides (Chart 1) were synthesized using Fmoc-chemistry on a Tribute® solid-phase 
peptide synthesizer (Gyros Protein Technologies AB, Tucson, AZ). After synthesis, the protection 
groups and resin in the peptidyl-resin were deprotected using an Fmoc-cleavage mixture 
containing 94% TFA, 3% TIPS and 3% water by stirring for 2 h at room temperature.50 The cleaved 
peptide and resin were separated using a filter with 70-170 µm pore size, and the filtrate containing 
the cleaved peptide was evaporated using a rotary evaporator. The dried peptide was reconstituted 
in 10 ml of 1:1 of acetonitrile: mobile phase A (95%water, 5%ACN and 0.1% TFA) and filtered 
using a 0.2 μm filter before injecting onto a semi preparative HPLC column (Waters XBridge C18 
column, 19 mm × 250 mm, 5 μm particle size; Waters Corporation, Milford, MA). The peptide 
was eluted at a flow rate of 15 ml/min and dried by lyophilization. The purified peptides were 
analysed for purity in a Waters Micromass LCT Premier Mass Spectrometer (Micromass Ltd., 
Manchester, U.K.).  
2.2.3. Photo-irradiation  
Solutions of 1 mM peptide and 100 µM 4-CB were prepared in 10 mM phosphate buffer and the 
pH adjusted to 3.30, 7.23, or 9.88 using HCl and/or NaOH. These solutions were saturated with 
either air or Ar, and photo-irradiated for 0-90 min at room temperature in borosilicate test tubes. 
The photo-irradiation was performed in a Rayonet photoreactor (RPR200, The Southern New 
England Ultraviolet Company, Branford, CT) equipped with four lamps (Southern New England, 




Actinometry was done with the ferrioxalate actinometer51-53, which gave a flux of ~3x10-8 
Einstein.s-1 and an irradiance of ~6.3 W.h/m2. The solutions in our experimental conditions was 
exposed to irradiances of 0-9.45 W.h/m2. The latter value is significantly below 200 W.h/m2 for 
photostability testing with UV light, recommended by the ICH Q1B guideline of the International 
Conference of Harmonization (ICH).54  Control solutions were placed in the dark at room 
temperature for 1 h or wrapped with aluminum foil and placed in the Rayonet photoreactor for 1 
h during photo-irradiation. All solutions were analyzed by HPLC and mass spectrometry.  
2.2.4. Reversed Phase-High Performance Liquid Chromatography (RP-HPLC) analysis 
Control and photo-irradiated solutions were analyzed in a RP-HPLC equipped with a PDA detector 
(Shimadzu Corporation, Kyoto, Japan). The unmodified peptides, photoproducts, and 4-CB were 
monitored at 214 nm. The separation was achieved at a flow rate of 1ml/min on a Vydac® 
218TP54 protein and peptide C18 column (4.6 mm i.d. x 250 mm, 5 µm particle size, and 300 Å 
pore size) (Alltech Associates Inc, Deerfield, IL), maintained at 35 °C in a column heater. Mobile 
phase A and B consisted of water with 0.1% TFA and ACN with 0.1% TFA, respectively. 
Resolution of unmodified peptides, photoproducts, and 4-CB was achieved with the following 
gradient program: 97% A and 3% B was held for 7 min, changed to 85% A and 15% B at 7.1 min, 
and linearly changed to 45% A and 55 % B within 14 min. Then, the composition of solvents was 
changed to 30% A and 70% B over 6 min and maintained for 1 min before re-equilibration to 3% 
A and 97% B for 7 min. The data were collected and analyzed with the Shimadzu LabSolutions 




2.2.5. NanoAcquity LC Electrospray Ionization Q-tof MS and LC-MS/MS analysis 
The photo-irradiated solutions were analyzed on a nanoAcquity Ultra Performance Liquid 
Chromatography system connected to a Xevo-G2 Qtof tandem mass spectrometer (LC-MS) 
(Waters Corporation, Milford, MA). The instrument was operated in the positive and data-
dependent mode at a mass range of 150-2000 Da. The capillary voltage and sampling cone voltage 
were set to 2.7 kV and 45 V, respectively. The electrospray ionization (ESI) source temperature 
was maintained at 100 °C. Four microliters of 20 μM control or photo-irradiated solutions were 
injected onto a Symmetry® C18 Waters trap column (2G-V/M Trap) with a dimension of 180 μm 
x 200 mm, 5 μm particle size, and 100 Å pore size, connected to an analytical nanoAcquity ultra 
performance Waters peptide CSH ™ C18 column with a dimension of 75 μm x 250 mm, 1.7 μm 
particle size, and 130 Å pore size.  The analytical column temperature was maintained at 40 °C. 
Mobile phase A consisted of Optima® water with 0.1% formic acid (FA) and mobile phase B 
consisted of acetonitrile containing 0.1% FA. The solutions were injected onto the trapping column 
for 2 min at a flow rate of 4 μl/min. After 2 min, the solutions were directed to the analytical 
column with a flow rate of 0.3 μl/min. The peptide and the photoproducts were separated using 
the following gradient: the initial composition was 97% A and 3% B mobile phases, which was 
changed linearly to 65% A and 35% B within 50 min, held for 20 min, changed to 5% A and 95% 
B at 70 min and held for another 3 min. Subsequently, the composition was reverted to 97% A and 
3% B to re-equilibrate the column and held for 10 min. The mass spectrometer was operated and 
the obtained data analyzed with the Masslynx v.4.1 software. The data were plotted with the 





2.3.1. Identification of photoproducts  
The solutions containing peptide M1 and 4-CB in 10 mM phosphate buffer were exposed to UV-
A light for 0-90 min; representative data for 60 min will be discussed in detail. When the solution 
at pH 7.23 was photo-irradiated under air or Ar with λmax = 350 nm for 60 min, several 
photoproducts were resolved and characterized by LC-MS analysis (Fig. 1, red trace). The 
photoproducts with their names, abbreviations, m/z value, and charge state are provided in Table 
S1. The control solution only showed the unmodified peptide M1 (tR = 21.20 min) displaying a 
molecular ion with m/z 397.73 (z = 2), and a small amount of oxidation products M1P6a and 
M1P6b with m/z 405.70 (z = 2), eluting at 20.96 min and 21.23 min, respectively (Fig. 1, black 
trace).  
When M1 was photo-irradiated at pH 7.23 under air (red trace), ~30% of the unmodified M1 were 
lost (Table S2), leading to the formation of several photoproducts that eluted before and after the 
peak of unmodified M1. LC-MS analysis revealed that the photoproducts M1P6a and M1P6b, 
eluting at tR = 20.96 and 21.23 min display a molecular ion with m/z 405.70 (z = 2), an increase 
of 16 Da relative to M1. At tR = 21.84 and 22.04 min, isobaric photoproducts (M1P1a and M1P1b) 
nearly co-eluted, displaying molecular ions with m/z 381.70 (z = 2), representing a loss of 32 Da 
from M1 (more details in section 3.3). At tR = 22.84 min, a photoproduct (M1P2) displaying a 
molecular ion with m/z 389.70 (z = 2) was observed and characterized by the loss of 16 Da from 
unmodified M1 (more detail in section 3.7). Another photoproduct that elutes before unmodified 
M1, at tR = 23.82 min, is M1P3, displaying a molecular ion with m/z 390.70 (z = 2), which is more 
prominent at pH 3.30 shown in Fig. 2 (green trace). The photoproducts that elute at tR = 26.80 and 




(more detail in sections 3.8 and 3.11). Photoproducts M1P5a-d, eluting at tR = 28.55, 29.05, 30.01, 
and 30.75 min, all display a molecular ion m/z 510.72 (z = 2). These isobaric products reveal an 
increase by 226 Da relative to M1, corresponding to the molecular weight of 4-CB. Therefore, 
products M1P5a-d are likely generated by reaction between peptide-derived radicals and a ketyl 
radical derived from 4-CB (more detail in section 3.10). The extracted ion chromatogram (XIC) 
of a photo-irradiated solution also revealed His oxidation products (more detail in section 3.12). 
All observed products are discussed in detail below. In contrast to air-saturated solutions, the 
photo-irradiation of Ar saturated solutions M1 and 4-CB (Fig. 1, blue trace) showed a significant 
lower conversion of M1 (7%), generating small yields of M1P1a/M1P1b, and products M1P5a-d. 
The structures of photoproducts from peptide M1 is shown in Chart 2. As a control, the solution 
containing peptide A1 with 4-CB was photo-irradiated in the similar conditions as M1 and 4-CB. 
As expected, the products generated from the original Met were not observed, including M1P1a 
and M1P1b (Fig. S1). 
2.3.2. Comparison of photoproducts at pH 3.30, 7.23, and 9.88 by LC-MS 
Control and photo-irradiated solutions of M1 and 4-CB in 10 mM phosphate buffer, at pH 3.30, 
7.23, or 9.88 (under air) were analyzed by LC-MS (Fig. 2). The control solutions were wrapped in 
aluminum foil and placed in Rayonet reactor during photo-irradiation. The control solutions 
contained <3% of oxidation products M1P6a and M1P6b, characterized by an increase of 16 Da 
on the Met residue. In general, photo-irradiation at pH 3.30 generated higher yield of 
photoproducts as compared to pH 7.23 and 9.88 (Table S2). At pH 3.30, M1 was converted into 
M1P6a/ M1P6b (tR = 20.96 and 21.23 min), M1P1a/M1P1b (tR = 21.81 and 22.04 min), M1P2 (tR 
= 22.84 min), M1P3 (tR = 23.82 min), M1P4 (tR = 23.91 min), M1P3+SO3H (tR = 26.80 min), 




M1P4a/M1P4b was not observed and at pH 9.88, only 0.11% of M1P4a/M1P4b was formed, 
which is ~4% less in comparison to pH 3.30 (Table S2). The percentages of M1P3 formed at pH 
7.23 and at pH 9.88 were 0.03 and 0.05, respectively, whereas at pH 3.30, 0.48% of M1P3 was 
formed. Similar observations were made when photoproducts at pH 3.30, 7.23, and 9.88 were 
analyzed by HPLC coupled to UV-detection (Fig. S2).   
2.3.3. The photoproducts M1P1a and M1P1b 
At tR = 21.84 and 22.04 min (Fig. 1, red trace), two isobaric photoproducts (M1P1a and M1P1b) 
were identified by LC-MS analysis, displaying molecular ion with m/z 381.72 (z = 2). These ions 
indicate a loss of 32 Da from M1. The LC-MS/MS spectrum of M1P1a/M1P1b was compared 
with that of unmodified M1 (Fig. 3) to elucidate structural changes leading to M1P1a/M1P1b. The 
LC-MS/MS spectrum of unmodified M1 revealed all the y-ions (y1-y6), a b2 ion, and several 
internal fragments such as HA, MH, LMH, LMHA, PLMH, and PLMHA, confirming that the 
amino acids in M1 were not modified (Fig. 3A). In contrast, the LC-MS/MS spectrum of 
M1P1a/M1P1b showed the y1 ion, and multiple y ions undergoing loss of water such as y4-H2O, 
y5-H2O, y5-H2O, and y6-H2O. Additionally, it displays internal fragments characterized by neutral 
water loss or neutral CO loss. All internal fragments are present with cross-link between oxidized 
Met and His. Importantly, prominent ions such as y3 and the internal fragment HA, which are 
present in LC-MS/MS spectrum of unmodified M1, are absent in the LC-MS/MS spectrum of 
M1P1a/M1P1b. Moreover, the intensity of immonium ion of His is decreased significantly in the 
LC-MS/MS spectrum of M1P1a/M1P1b. These data suggest a cross-link formation between the 
original residues Met and His after the loss of 32 Da. Another important observation is that 
M1P1a/M1P1b loses a water molecule during LC-MS/MS analysis, resulting in a product 




M1P1a/M1P1b-H2O have identical fragmentation patterns (Fig. S3) indicating that they are related 
to each other. Based on the LC-MS/MS spectrum of M1P1a/M1P1b, we propose a mechanism in 
Scheme 1, according to which M1P1a/M1P1b is derived from aspartate semialdehyde M1P1 
(reaction 8). M1P1 is also isobaric to M1P1a/M1P1b; however, the LC-MS/MS spectrum of m/z 
381.72 (z = 2) did not show fragmentation pattern for open chain aldehyde. M1P1a/M1P1b must 
be in equilibrium with M1P1 as shown in reaction 8 Scheme 1. In order to prove the existence of 
the aspartate semialdehyde M1P1, the photo-irradiation samples were subjected to reduction by 
NaBH4 and derivatization with GRT, as described below.  
2.3.3.1. Reduction by NaBH4 
When a photo-irradiated solution was incubated with 20 mM NaBH4 at 37 °C for 15 min at pH 
12.00 and analysed by LC-MS (Fig. 4), the peaks with m/z 381.72 (z =2), representing 
M1P1a/M1P1b disappeared and a new peak at tR = 21.23 min appeared. This new peak contained 
a product with a molecular ion with m/z 382.70 (z =2), indicating an increase of 2 Da relative to 
M1P1a/M1P1b. As M1P1a/M1P1b are connected to M1P1 via equilibrium 8 Scheme 1, reduction 
process converts aspartate semialdehyde M1P1 into an alcohol as shown in Scheme 3.  
2.3.3.2. Derivatization by GRT 
The photo-irradiated solution was subjected to derivatization with GRT, which forms a hydrazone 
derivative of aldehydes. A photo-irradiated solution was incubated with 20 mM GRT at 37 °C and 
pH 3.30 for 19 h and analysed by LC-MS. This reaction resulted in the reduction of peak area of 
the signal representing M1P1a/M1P1b and the formation of a new peak at tR = 17.52 min 
containing a product with a molecular ion with m/z 438.23 (z = 2) (Fig. 5, insert). This peak 
contains the hydrazone derived from M1P1 (M1P1-GRT) shown in Scheme 4. The LC-MS/MS 




hydrazone, depicting a chemical modification of the original Met residue (Fig. S4), further 
indicating that M1P1a/M1P1b are in equilibrium with M1P1.  
2.3.4. Generation of M1P1a/M1P1b from peptide M1 containing 13C-Met 
The LC-MS/MS spectrum of M1P1a/M1P1b suggests a cross-link between the original residues 
Met and His after the loss of 32 Da. In order to evaluate whether the loss of 32 Da originates from 
Met and His, peptide M1 was synthesized with stable isotope-labeled Met (ε-13C) (M2) or His 
(15N3; section 3.5) (M3). One pathway to the loss of 32 Da would be oxidation of Met to aspartate 
semialdehyde (M1P1), accounting for a net loss of 32 Da. A solution containing 1 mM peptide M2 
and 100 µM 4-CB was photo-irradiated at pH 7.20 under the same conditions as outlined in section 
2.3. The LC-MS chromatogram of the photo-irradiated solution shows that unmodified M2 and 
several photoproducts are higher in mass by 1 Da; however, the cross-link M1P1a/M1P1b derived 
from peptide M2 shows an identical molecular ion (m/z 381.70, z = 2) as M1P1a/M1P1b derived 
from peptide M1, indicating that the original Met residue had lost the ε-CH3 group, consistent with 
a loss of 13CH3SH to form aspartate semialdehyde, M1P1.  
2.3.5. Generation of M1P1a/M1P1b-(15N3) from peptide M3 containing 15N-labeled His 
Theoretically, a loss of 32 Da from M1 would also be consistent with a loss of hydrazine (H2N-
NH2), which could originate from His. Therefore, peptide M3 (Chart 1) was synthesized and 
subjected to photo-oxidation and LC-MS/MS analysis. The LC-MS chromatogram showed 
formation of M1P1a/M1P1b-(15N3) with an increase of 3 Da in comparison to M1P1a/M1P1b 
derived from peptide M1. The LC-MS/MS spectrum of M1P1a/M1P1b-(15N3) (Fig. 6) revealed 
the presence of y4-y6 including their neutral loss of H2O and absence of y2 and y3. The internal 




oxidized Met and  His(15N3) characterized by neutral water loss or neutral CO loss. The LC-
MS/MS spectrum indicates the side chain of the His residue is intact, and Met and His(15N3) are 
cross-linked after the loss of 32 Da and a water molecule, like M1P1a/M1P1b. Hence, the 
experiments with M2 and M3 are consistent with the structural assignment of product 
M1P1a/M1P1b derived from peptide M1. 
2.3.6. Effect of spacing on cross-link formation 
Two model peptides M4 and M5 containing one Gly and two Gly, respectively, between Met and 
His were synthesized to observe the effect of spacing between Met and His in cross-link formation. 
Solutions containing either M4 or M5 and 4-CB were photo-irradiated under the conditions 
outlined in section 2.3 and the products were analysed by LC-MS/MS. The cross-link product 
formed from M4 (M4P1a/M4P1b) displays a molecular ion with m/z 410.27 (z = 2) corresponding 
to the loss of 32 Da from M4. The LC-MS/MS spectrum of M4P1a/M4P1b (Fig. 7) displays the 
characteristic ions y2, y5-H2O, y6-H2O, and y7-H2O. All internal fragments contained cross-linked 
oxidized Met, Gly, and His, characterized by loss of neutral H2O loss or neutral loss of CO. 
Together with the absence of y3 and y4 ions and of the internal fragments that would contain either 
Met or His, these data are consistent with cross-link formation between Met and His across a 
bridging Gly residue. It is interesting that the LC-MS/MS spectrum in Fig. 7 shows a small signal 
for the His immonium ion, suggesting that the cross-link may be sensitive to dissociation during 
electrospray LC-MS analysis, consistent with equilibrium 8 (Scheme 1). 
The cross-link product M5P1a/M5P1b formed from peptide M5 was analyzed by LC-MS/MS. The 
LC-MS/MS spectrum of M5P1a/M5P1b (Fig. 8) displayed the ions y2, y3, y6-H2O, y7-H2O, and 




ion y3 and the internal fragment HA are observed at low intensity, which indicates that the cross-
link with a Gly-Gly bridge may not be stable during electrospray LC-MS analysis. However, like 
M1P1a/M1P1b and M1P1a/M1P1b-(15N3), we observed loss of water from the molecular ion 
during gas-phase fragmentation from M4P1a/M4P1b and M5P1a/M5P1b, analogous to the 
formation of M1P1a/M1P1b-H2O from M1 according to reaction 9.  
2.3.7. Formation of aspartic acid (M1P2) 
The photoproduct M1P2 is characterized by the loss of 16 Da from M1, with m/z 389.72 (z = 2). 
In Fig. 1, M1P2 eluted at tR = 22.84 min and the y ion series (y1-y6) in the LC-MS/MS analysis 
(Fig. 9) indicated that the loss of 16 Da is derived from the Met residue of M1. This is confirmed 
by the fragments such as HA, MH-16, LMH-16, PLMHA-16, and the immonium ions of His, Pro 
and Leu. A net loss of 16 Da from Met would be consistent with the formation of thioaldehyde, 
vinyl homocysteine, or aspartic acid; all these proposed structures are isobaric. In order to test 
whether M1P2 was a thioaldehyde, the photo-irradiated solution was incubated with GRT, which 
would convert the thioaldehyde in a hydrazone, analogous to the derivatization of aspartic 
semialdehyde (section 3.3.2). However, the incubation with GRT did not change the peak intensity 
of M1P2, suggesting that this product is not a thioaldehyde. This was confirmed by reaction with 
NaBH4, which did not result in any reduction product.  
The second possible structure is vinyl homocysteine that contains a free thiol group. When photo-
irradiated sample was incubated with the alkylating agent NEM at 37 °C for 1 h at pH 9.20, the 
peak intensity of M1P2 did not change, indicating that M1P2 does not contain a free thiol. 




(Scheme 1). M1P2 can also form after oxidation of aspartate semialdehyde (M1P1) via reaction 
11 Scheme 1.   
2.3.8. Formation of homocysteine (M1P3) and homocysteine sulfonic acid (M1P3-SO3H)  
The photoproduct M1P3 eluting at tR = 23.82 min (Fig. 1), displays a molecular ion with m/z 
390.70 (z = 2), corresponding to the loss of 14 Da from M1. The LC-MS/MS spectrum of M1P3 
(Fig. 10) showed the presence of ion series y1-y6, indicating the loss of 14 Da from the Met 
residue. Moreover, the LC-MS/MS spectrum also displayed the immonium ions of Pro, Leu, and 
His, and internal fragments such as HA, MH-14, LMH-14, and PLMHA-14, indicating that 
modification of the Met residue is responsible for the formation of M1P3. A loss of 14 Da from 
Met would be consistent with the formation of homocysteine, which has been observed before as 
a product of Met>S•+.25 Since homocysteine contains a free thiol group, the photo-irradiated 
solution was incubated with NEM at 37 °C for 1 h at pH 9.20. This incubation led to a new product 
with m/z 453.26 (z = 2), indicating the alkylation of M1P3 with NEM (Scheme 5). LC-MS/MS 
analysis of this NEM alkylated product (Fig. S5) displayed the expected ion series y2-y6, showing 
the addition of NEM to homocysteine (M1P3-NEM). In addition, the presence of internal 
fragments such as HA and u2H (where u2 = homocysteine + NEM) indicate the formation of 
homocysteine.  
The photo-oxidation of M1 in the presence of 4-CB led to a peak eluting at tR = 26.80 min (Fig. 1, 
red trace), which displays a molecular ion with 414.72 (z = 2), corresponding to an addition of 
either 34 Da to M1 or 48 Da to M1P3. LC-MS/MS analysis (Fig. S6) of this peak reveals the ion 
series y1-y6, consistent with the oxidation of M1P3 to homocysteine sulfonic acid (product M1P3-




internal fragments such as HA and u3H (where u3 = homocysteine + 48). Interestingly, based on 
the relative signal intensities the yield of M1P3-SO3H is four-fold and ~seven-fold higher at pH 
3.30, compared to oxidation at pH 7.23 and 9.88, respectively (Fig. 2 and Table S2).  
2.3.9. Formation of thioesters (M1P4a and M1P4b) 
A photoproduct of M1 eluting at tR = 23.91 min (Fig. 2, green trace) displays a molecular ion with 
m/z 404.72 (z = 2). This m/z may correspond to either M1P4a or M1P4b isomers. This 
photoproduct was only observed at pH 3.30, but not at pH 7.23 and 9.88. The molecular ion 
indicates an increase of 14 Da relative to M1. The LC-MS/MS spectrum of M1P4a/M1P4b (Fig. 
11) displays immonium ions of Pro, Leu, and His, several internal fragments such as HA and 
LPLMH+14 and all the y-ions except for y4, which indicates that the chemical transformation 
targeted the Met residue. The molecular weight of M1P4a/M1P4b is consistent with the formation 
of a thioester, likely via reactions 6 (Scheme 1) and 14 (Scheme 2), respectively.  
In order to confirm the formation of thioester from peptide M1, the photo-irradiated solution was 
incubated with NaBH4 (Fig. 4), where the C=O of thioester may be reduced to an alcohol, similar 
to mechanism shown in Scheme 3. The reduced product will increase by 2 Da compared to M1P4 
and give a molecular ion of 405.72 (z = 2), which is isobaric to MetO. After incubation, the peak 
corresponding to M1P4a/M1P4b disappeared. Since the reduced product is isobaric to MetO, it 
was difficult to identify it. Therefore, a separate derivatization experiment was carried out with 
GRT for 19 h at 37 °C in acidic pH, where C=O may form a hydrazone with GRT. However, we 
did not observe the derivatized product, instead higher yield of M1P3 was observed (Fig. 5). 




M1P3 (reaction 16 Scheme 2). Similarly, M1P4a can also undergo acid hydrolysis to give M1P2 
but our data did not indicate increase in M1P2. 
2.3.10.  4-CB adducts on Met (M1P5a-d) 
The photoproducts displaying molecular ions with m/z 510.72 (z = 2) (Fig. 1) are present in at 
least four distinct peaks referred to as (M1P5a-d) and correspond to an increase of 226 Da (mass 
of 4-CB) relative to M1. They elute at tR = 28.55, 29.05, 30.01, and 30.75 min. These peaks 
collectively represent 4-CB adducts either on the C3 or the C5 carbon of Met, which can be 
generated as various epimers. Such 4-CB adduct on Met have been reported previously.55 
Theoretically, we expected to observe four on the C3 carbon and two on the C5 carbon; as we can 
resolve only four distinct epimers, two of these epimer either do not form or co-elute with other 
epimers. Representative LC-MS/MS spectrum of M1P5b (Fig. 12) eluting at tR = 30.01 min reveals 
the ions y1, y2, y3, y4-H2O, y5-H2O, y6-H2O, immonium ions of Pro, Leu, and His, and internal 
fragments such as HA, MH+226-H2O; all of these ions indicate that the addition of 226 Da 
occurred on the Met residue of M1.  
2.3.11.  Formation of Met sulfoxide (M1P6a/M1P6b) and sulfone (M1P7)  
The LC-MS chromatograms (Fig. 1) of control and photo-irradiated solutions of M1 and 4-CB 
displayed two peaks eluting at tR = 20.96 and 21.23 min containing molecular ions with m/z 405.72 
(z = 2), corresponding to an increase of 16 Da on M1. However, the photo-irradiated sample 
contained a higher intensity of these isobaric products. The LC-MS/MS spectra of these isobaric 
products (Fig. S7) were identical and revealed the ion series y1-y6, immonium ions of Pro, Leu, 
and His, and the internal fragments such as HA and MH+16, indicating an increase of 16 Da on 




In addition, the photo-irradiated solution also revealed a peak eluting at tR = 27.17 min displaying 
a molecular ion with m/z 413.72 (z = 2), which corresponds to addition of 32 Da relative to peptide 
M1.  The LC-MS/MS spectrum (Fig. S8) of this peak displays the ion series y1-y6, indicating that 
the increase of 32 Da occurred on the Met residue of M1.  In addition, the presence of immonium 
ions of Pro, Leu, and His residue indicates that these residues are not modified, and the presence 
of internal fragments such as HA and MH+32 further solidifies our observation that the Met 
residue is modified. The increase in 32 Da is consistent with the formation of M1P7.  
2.3.12.  Formation of His oxidation products (M1P8 and M1P9) 
The photo-irradiation of M1 and 4-CB leads to two peaks eluting at tR = 28.04 and 29.27 min, 
displaying isobaric molecular ions with m/z 826.37 (z = 1), corresponding to an increase of 32 Da 
relative to M1. The LC-MS/MS spectra of these peaks (Fig. S9) are identical and display the ion 
series b2-b6 and the b5-H2O, indicating an addition of 32 Da to the His residue. This is 
corroborated by the absence of a His immonium ion, and the presence of immonium ions of Pro, 
Leu and Met. The two isobaric products (M1P18a and M1P8b) likely represent a 2,4-dihydroxy 
derivative of His and/or an endoperoxide, likely generated through the addition of singlet oxygen 
to His.56 Singlet oxygen can be generated under our experimental condition through reaction of 
*4-CB with O2.57-58  
Additional photoproduct (M1P7), eluting at tR = 45.85 min, displays a molecular ion with m/z 
808.4 (z = 1), corresponding to an increase of 14 Da relative to peptide M1. The LC-MS/MS 
spectrum (Fig. S10) of this peak displays the ion series b2-b5, which indicate that the increase of 




the internal fragment HA. The mass increase of 14 on M1P9 is consistent with the formation of 4-
alkyl-2H-imidazol-2-one (see Chart 2), a commonly observed His oxidation product. 
2.4. Discussion 
The photo-irradiation of M1 and 4-CB formed a series of photoproducts that were identified by 
LC-MS/MS analysis. Peptide M1 contains two reactive amino acids (Met and His) in its sequence 
and we detected the photoproducts of Met were in higher yield compared to photoproducts of His. 
While generation of most of the Met photoproducts were proposed via Met>S•+, photoproducts in 
His may be generated via singlet oxygen. This is explained by the two types of photo-oxidation of 
4-CB, where type I generates Met>S•+ after abstraction of an electron by 4-CB and in type II 
photo-oxidation triplet state 4-CB transfers energy to a molecular oxygen generating singlet 
oxygen.59 The formation of Met>S•+, a key intermediate in our study, can be stabilized by nearby 
heteroatoms (N, O or S) forming 2c-3e bond, identified by pulse radiolysis.31-32 
The hydrogen on C3 or C5 carbons of Met>S•+ is deprotonated forming a carbon-centered radical, 
which can react readily with oxygen under air. These stable intermediates are important for the 
transformation of Met to photoproducts. However, under Ar these carbon-centered radicals do not 
react with oxygen to give oxidation products. As such, these carbon-centered radicals react more 
readily with 4-CB to give M1P5(a-d) photoproducts (Fig. 12). We have observed that the 
intensities of 4-CB adduct on Met residues are higher under Ar than under air. Apart from the role 
of oxygen to form these photoproducts of Met and His, we also looked into the effect of pH on the 
products formation at pH 3.30, 7.23, and 9.88. We detected a higher yield of photoproducts and 
new peaks at pH 3.30 compared to pH 7.23 and 9.88 (Table S2). This is likely because of the initial 




generating more Met>S•+ and subsequently more photoproducts. One of the photoproducts 
detected was a cross-link product, M1P1a/M1P1b, which has not been reported previously. 
2.4.1. Formation of M1P1a/M1P1b 
Among many Met photoproducts observed, formation of the cross-link product M1P1a/M1P1b 
was the most notable product detected after photo-irradiation. M1P1a/M1P1b is characterized by 
the loss of CH3SH from Met residue, formation of aldehyde on C3 carbon of oxidized Met, and 
attack by nitrogen of imidazole on aldehyde forming a cross-link. While there are studies on 
hydrolysis between Met and His in hGH and IgG1 as well as the effects of Met oxidation in IgG1 
on binding ability of His with FcRn, no direct cross-link formation between Met and His side 
chains was reported previously. Considering the frequency of Met-His sequence in proteins, a 
mechanistic study for M1P1a/M1P1b formation is thoroughly studied.  
The LC-MS/MS spectrum of M1P1a/M1P1b (Fig. 3B) indicates the formation of a cross-link 
product (section. 3.3). M1P1a/M1P1b formation involves multistep pathways and is initiated after 
the diffusion-controlled reaction between carbon-centered radical at C3 position of Met residue 
and a molecular oxygen forming a peroxyl radical (reaction 4, Scheme 1). Two of these peroxyl 
radicals combine and undergo Russell mechanism to give M1P4, a molecular oxygen, and an 
alcohol product, one of the intermediates of M1P1a/M1P1b (reactions 5 and 6, Scheme 1). We 
detected M1P4 in the LC-MS chromatogram at pH 3.30. At higher pHs, M1P4 may have 
hydrolyzed faster to give aspartic acid (M1P2), which was observed in all pHs. The detection of 
these two products in LC-MS chromatogram solidifies our proposed mechanism. Further, to form 
M1P1a/M1P1b, the alcohol intermediate forms an aspartate semialdehyde (M1P1) after loss of 




nucleophilic reaction occurs when nitrogen of imidazole attacks M1P1 forming a cross-link 
product, M1P1a/M1P1b (reaction 8, Scheme 1). The formation of M1P1a/M1P1b is also 
corroborated by our studies on isotopically labelled peptides M2 and M3. When C5 on Met was 
labelled with 13C in M2, a cross-link product was observed with no change in m/z in comparison 
to M1P1a/M1P1b depicting loss of this carbon during the formation of the product as we have 
proposed in our mechanism. In addition, three nitrogen on His were isotopically labelled in M3, 
and after photo-irradiation a cross-link product with increase in 3 Da was observed (Fig. 6) 
indicating no loss of mass from His. Notably, M1P1a/M1P1b also undergoes loss of a water 
molecule in LC-MS (reaction 9, Scheme 1), which seems to be a common phenomenon on our MS 
settings as we also observed loss of water in the LC-MS/MS spectrum of 4-CB adducts on Met 
(Fig. 12) when an alcohol group was formed.  
Few cross-links in proteins have been reported in the literature, mainly due to difficulty in 
identifying them without prior knowledge of mechanisms of formation, sites of cross-linking, and 
lack of MS data search engines.46 Covalent chemical cross-linking is of major concern in 
biotherapeutics as it can lead to non-reducible aggregates and result in loss of biological activity 
and increase immunogenicity.43-45 This can affect the product quality, safety, and clinical efficacy. 
For example, previous studies reported on cross-linking formation of His-His cross-link, which 
may have resulted in a non-reducible aggregate.46 His is also known to cross-link with other amino 
acids, such as Lys and Cys.61 Identification of cross-links may provide insight into the 
pathogenesis of conditions such as Alzheimer62-63 and cataract63-64 as protein aggregation is known 
to be a key factor in their development. Therefore, it is crucial to identify these non-reducible 
cross-links and understand their underlying mechanism; also, development of the cross-link 





This chapter reports on the formation of a novel cross-link product between modified Met and His 
in a model peptide along with other Met and His oxidation products after photo-irradiation with 4-
CB. The mechanism and supporting experiments for the cross-link formation are provided in 
detail. The mechanism primarily involves the formation of sulfur radical cation on Met residue 
leading to a radical on C3 carbon, loss of methanethiol (CH3SH), and formation of an aldehyde, 
which is attacked by nitrogen on imidazole to form the cross-link product. Such modification on 
Met is irreversible and can change the structure and functionality of proteins. The prevalence of 
Met and His sequence in therapeutic proteins and their importance in protein efficacy make this 
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2.7. Charts and Figures 
Chart 1: The structures and abbreviations of the model peptides synthesized to study the effect of 























































Chart 2: The proposed structures of photoproducts generated after irradiation of M1 with 4-CB at 
λmax = 350nm for 1 h. R1=LPL, R2=AL, and R3=HAL. P3a, P5a, P7a and P9a have similar structure 
as P1a and P3b, P5b, P7b and P9b have similar structure as P1b. P5a and 5b products contains 
three isotopically labelled nitrogen in His, P7a and P7b contains one Gly between Met and His, 
and P9a and P9b contains two Gly between Met and His (structures not shown).  
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Methionine sulfone M1P7 
 
Fig. S8 











































Figure 1: Full LC-MS chromatograms of photoproducts of peptide M1 and 4-CB in 10 mM 
phosphate buffer, pH 7.23 upon exposure to UV-A light with λmax = 350 nm  for 1 h under air (red-
trace), argon (blue-trace) and aluminum wrapped control under air (black-trace). (Note: Refer to 





























Figure 2: Full LC-MS chromatograms of photoproducts of  peptide M1 and 4-CB in 10 mM 
phosphate buffer upon exposure to UVA light with λmax = 350 nm  for 1 h under air at pH 3.30 
(red-trace), pH 7.23 (blue-trace), pH 9.88 (red-trace), and aluminum wrapped control-at pH 3.30 































Figure 3: LC-MS/MS spectra of (A) unmodified M1 and (B) cross-link product, M1P1a/M1P1b, 























Figure 4: LC-MS full chromatograms of photo-irradiated M1: without NaBH4 (black-trace) and 





























Figure 5: LC-MS full chromatograms of photo-irradiated M1: without GRT (black-trace) and 





























Figure 6: LC-MS/MS spectrum of M1P1a/M1P2-(15N3), a cross-link with three isotopically 

















































































































































































Figure 12: Representative LC-MS/MS spectrum of M1P5 at C3 position. This LC-MS/MS may 








Scheme 1: Proposed mechanism of product formation: M1P1a, M1P1b, and M1P2. R1 = LPL and 





















Scheme 3: Proposed mechanism for the reduction of M1P1 with NaBH4. R1 = LPL and R2 = AL 
amino acids. 
 



























































Figure S1: LC-MS chromatograms of (A) aluminum wrapped control LPLAHAL with 4-CB and 



















Figure S2: RP-HPLC chromatograms of photoproducts of peptide M1 and 4-CB in 10 mM 
phosphate buffer upon exposure to UV-A light with λmax = 350 nm  for 1 h under air at pH 3.30 



















































Figure S4: LC-MS/MS of M1P1-GRT derivatized product with m/z 438.27 (z =2), where u1 = 


























Figure S5: LC-MS/MS spectrum of M1P3-NEM alkylated product with m/z 453.26 (z = 2), 



























Figure S6: LC-MS/MS spectrum of M1P3-SO3H with m/z 414.69 (z = 2), where u3 = 



































































































































Table S1: The proposed photoproducts generated after photo-irradiation of M1 and 4-CB at λmax 
= 350 nm for 1 h. 
Names of M1 photoproducts  Abbreviation m/z  z 
    
Aspartate semialdehyde M1P1a 381.72 2 
Met-His cross-link  M1P1b 381.72 2 
Aspartic acid M1P2 389.72 2 
Homocysteine M1P3 390.70 2 
Homocysteine sulfonic acid M1P3-SO3H 414.72 2 
Thioester M1P4a/M1P4b 404.72 2 
4-CB adducts M1P5(a-d) 510.72 2 
Methionine sulfoxide M1P6a/M1P6b 405.72 2 
Methionine sulfone M1P7 413.72 2 
2,4-dihydroxy-His or endoperoxide M1P8 826.37 1 

















Table S2: Relative percent yield of unmodified peptide M1 remained and photoproducts formed 
after photo-irradiation of M1 and 4-CB at λmax = 350 nm for 1 h. 
  pH 3.3 pH 7.23 pH 9.88 
        
M1 61.00 70.92 56.14 
M1P1a 2.36 3.08 1.17 
M1P1b 8.81 1.40 1.80 
M1P2 2.72 0.97 0.37 
M1P3 0.48 0.03 0.05 
M1P3-SO3H 1.83 0.47 0.28 
M1P4a/M1P4b 0.43 0.00 0.11 
M1P5a 0.11 0.10 0.11 
M1P5b 0.19 0.24 0.26 
M1P5c 0.32 0.48 0.32 
M1P5d 0.16 0.22 0.17 
M1P6a 8.43 9.78 9.83 
M1P6b 9.33 10.76 9.58 
M1P7 3.84 0.93 1.45 
M1P8a 0.00 0.16 0.17 
M1P8b 0.00 0.40 18.10 




 Chapter 3: Visible light degradation of a monoclonal 
antibody in a high concentration formulation: 
characterization of a tryptophan-derived 
chromophoric photoproduct by comparison to 





The development and approval of biotherapeutics, especially monoclonal antibodies (mAbs), has 
been on the rise because of the high specificity and efficacy leading to enhanced patient safety.1 
Most commonly, mAbs are used for the treatment of cancer, autoimmune diseases, allergic 
diseases, asthma, and for organ transplants.2-4 mAbs have been formulated at low concentrations 
for intravenous infusion. Since this is time-consuming and requires the patient to be in a hospital 
setting, biopharmaceutical companies have been exploring other routes of administration such as 
subcutaneous (SC) injections, which can be administered by patients at home and require only a 
few minutes of injection time; as mAbs are formulated based on mg/kg and SC injections 
necessitate a small volume (<1.5 ml), mAbs for this route have to be formulated at concentrations 
above 100 mg/ml.5 At such high concentrations, viscosity problems are prominent and can 
complicate the injection process due to greater syringe back pressure and pain at the injection site.6-
7 The viscosity of mAbs can be overcome by the addition of salts (such as NaCl) and amino acids 
such as lysine (Lys), arginine (Arg), and histidine (His).8 This is accomplished either by 
electrostatic interactions or by interaction with aromatic amino acids. In particular, His has been 
used in marketed formulation of mAbs, as this can act as a buffer and simultaneously reduce 
viscosity.9 Other potential problems associated with high mAb concentrations are aggregation, 
oxidation, and color change.10 According to the International Conference on Harmonization (ICH) 
Q6B, color change is a critical quality attribute for drug release11 and the protein formulation is 
expected to be clear to slightly yellow.12 This is because an atypical color may indicate the 
presence of impurities, contaminants, degradation of the protein, and/or excipients, which may 
negatively impact patient health. Therefore, it is important to investigate the root cause of such 




so far are associated either with the components added to the culture media during manufacturing, 
or with degradation products generated after exposure to light or elevated temperature during 
storage.  
During manufacturing, color changes in the culture fluid have been attributed mainly to three 
sources: (i) glucose (ii) B vitamins, and (iii) iron.13 When a high concentration of glucose is present 
in the culture media, glycation can occur, which may proceed to generate advanced glycation end 
products (AGEs).14 These can give rise to a yellow color to the solution.15 In addition, such AGEs 
may reduce the efficacy of a mAb or activate proinflammatory responses.16 The cell culture media 
also contains B vitamins, such as B12 (cobalamine) and B6 to increase antibody production. These 
vitamins can directly react with proteins or act as photosensitizers when exposed to light, leading 
to pink colored products.13, 17 The combination of iron with B vitamins can give a brown or brown-
yellow color under aerobic cell culture conditions. This is likely due to reactive oxygen species 
(ROS), generated via Fenton reaction17-19 or photo-Fenton reaction,20 which can oxidize proteins 
to chromophoric products. Specially the hydroxyl radical (HO•), a powerful oxidant, can convert 
tryptophan (Trp) to colored products such as N-formyl kynurenine (NFK) and kynurenine (Kyn).17-
18 More importantly, NFK and protein-bound Kyn are photosensitizers which can lead to 
secondary photooxidation.21-25  
During storage, previously colorless protein solutions may develop a yellow to brown-yellow 
color; such coloration is also observed after photostability testing to the recommendation of the 
ICH Q1B guideline (1.2 million lux hours of visible light and ≥200 Wh/m2 of UV light).4, 10 
Interestingly, such color change was also observed in highly concentrated mAb formulation during 
exposure to ambient light , at doses far below of that recommended by the ICH guideline.26 This 




visible light; however, photoproducts such as Kyn can absorb light along with the B vitamins such 
as vitamins B2 (riboflavin), B6, B9 (folic acid) and B12 (cobalamine).21 The latter can act as 
photosensitizers via type I and type II reactions.27 Apart from commonly known photoproducts of 
His and Trp, other products with chromophoric properties may be responsible for color in the 
formulation exposed to heat or light. One such product generated by the loss of 2 Da from Trp 
during storage at 25 °C for 12 months, displaying an absorption maximum at 335 nm.4 In addition, 
tyrosine derived photoproducts such as dihydroxyphenylalanine (DOPA)28 may lead to the 
coloration of light exposed formulation. Studies on the yellowing of sheep wool28 and lens 
proteins29-31 have led to the identification of several Trp and Tyr-derived oxidation products such 
as carbolines, hydroxykynurenine, and DOPA.  
In this chapter, we describe the formation of a chromophoric photoproduct of Trp during visible 
light exposure of a mAb in formulation containing sodium acetate (NaAc) or His/Lys buffer, and 
physical and chemical modifications accompanying yellow color formation. For structural 
characterization of the chromophoric photoproduct, we exposed a model compound, N-acetyl-L-
tryptophan amide (NATA), to visible light photo-irradiation in sodium acetate buffer, followed by 
HPLC-mass spectrometry (MS) and nuclear magnetic resonance (NMR) analysis.  
3.2. Materials and Methods 
The mAb (mAbZ) for this study was obtained from AstraZenaca. NaAc, L-His 
monohydrochloride, L-Lys monohydrochloride, NATA, formic acid (FA), bis(2-
mercaptoethyl)sulfone (BMS), iodoacetamide (IAA), and β-mercaptoethanol (β-ME) were 
purchased from Millipore Sigma (Burlington, MA). Borosilicate glass tubes, acetonitrile (ACN), 
Optima®  water with FA, Optima®  ACN with FA, acetic acid, and methanol were purchased 




MΩ) water, which was prepared freshly with a WaterPro PS Polishing System (Labconco, Kansas 
City, MO).  
3.2.1. Sample preparation 
The mAbZ formulation contained 0.01% PS80, 85 mM NaCl and was buffered in 50 mM NaAc 
at pH 5.5 (NaAc buffer). In order to prepare a formulation of mAbZ in His/Lys buffer, buffer 
exchange was performed with D-Tube™ Dialyzer Maxi (MWCO 3.5 kDa) in a container 
containing 2 L of 20 mM HisCl and 75 mM Lys at pH 5.50 (His/Lys buffer)  for 2 h at 4 °C. Then, 
the dialyzer containing mAbZ was transferred into a 5 L container of His/Lys buffer, pH 5.5,  and 
was dialyzed overnight at 4 °C. The samples were frozen at -80 °C until further experiments were 
performed. Solutions of 10 mM NATA either in NaAc, pH 5.5, or in His/Lys buffer, pH 5.5, were 
freshly prepared before the experiments.  
3.2.2. Photo-irradiation 
Solutions of mAbZ or NATA were photo-irradiated using eight RPR-4190A visible lamps (The 
Southern New England Ultraviolet Company, Branford, CT; λmax = 419 nm, emission spectrum 
between 390 and 475 nm), which were placed in a Rayonet Photoreactor (RPR200, The Southern 
New England Ultraviolet Company, Branford, CT). Photo-irradiation of the solutions were 
performed under air in borosilicate tubes. The lamps provided a flux of 6.44 x 10-8 Einstein/sec 





3.2.3.  Photo-irradiation of mAbZ and NATA 
Solutions containing 500 µl of 150 mg/ml mAbZ formulated either in NaAc or His/Lys buffer 
were photo-irradiated for 0-8 h under air. The control and photo-irradiated samples were either 
diluted as needed for further analysis or were digested for mass spectrometry analysis. Control 
samples were wrapped in aluminum foil and exposed to light for 8 h.  
NATA is a suitable model to study the degradation pathways of Trp under the same experimental 
conditions as mAbZ. Solutions of NATA formulated either in NaAc or in His/Lys buffer were 
exposed to visible light for 0-24 h. The samples were analyzed by reverse phase-high-performance 
liquid chromatography (RP-HPLC), HPLC-MS, and NMR to identify photoproducts. Specially a 
photoproduct with the same UV/Vis spectroscopic properties as observed for mAbZ was fraction 
collected, lyophilized, and re-concentrated in DMSO. The concentrated sample was analyzed by 
HPLC-MS and  1H- and 13C-NMR. 
3.2.4.  Reducing and Non-reducing SDS-PAGE 
Control and photo-irradiated mAbZ solutions were diluted to 1 mg/ml and combined with Laemmli 
buffer in a 1:1 ratio. Forty µl of the mixture was loaded onto each polyacrylamide gel well (4-20% 
Mini-Protean® TGX™ Precast Gels, Bio-Rad, Hercules, CA), and molecular weight markers were 
used for molecular weight calibration. For reducing gels, 50 µl of 13 M β-ME was added to the 
Laemmli buffer with the protein and incubated for 1 h at 50 °C  before running the gels at 200 V. 
Both gels were stained with Coomassie Brilliant Blue R-250 (Amersham Pharmacia Biotech AB, 
Uppsala, Sweden) and destained using 50% MeOH and 10% acetic acid in water for visualization 




3.2.5. Size Exclusion Chromatography (SEC) 
Control and photo-irradiated mAbZ were diluted from 150 mg/ml to 1 mg/ml either in NaAc or 
His/Lys buffer. SEC chromatography was run on a HPLC instrument (Shimadzu, Kyoto, Japan). 
Fifty μg of mAbZ were injected onto a TSK-Gel SWXL guard column (6.0 mm x 40 mm) and 
directed to a TSK-Gel G3000SWXL SEC column (7.8 mm x 300 mm) at a flow rate of 0.7 ml/min. 
The column temperature was maintained at 30 °C in a column heater, and monomer and higher 
molecular weight species (HMWS) eluted with 200 mM phosphate buffer, pH 6.8.  Detection was 
achieved at 220 nm with a diode array detector (Shimadzu, Kyoto, Japan). The percentage of 
monomers and HMWS were calculated relative to the total peak areas detected in the SEC 
chromatograms.  
3.2.6. Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) was performed on a MicroCal VP-Capillary calorimeter 
(Malvern Instruments, Malvern, UK) equipped with an autosampler. Samples of 300 μl volume 
containing 1 mg/ml mAbZ were stored in a sealed 96-well plate in an autosampler, kept at 4 °C. 
Temperature ramps were from 10 to 90 °C at a scan rate of 2 °C/min. A 15 min equilibration period 
at 10 °C was performed prior to each run. All thermograms were buffer subtracted, baseline 
corrected, and normalized for protein concentration. Apparent melting temperatures were 
calculated by fitting thermograms to a non-two-state equilibrium model in Origin 7.0 (OriginLab). 
Onset melting temperatures, Tonset, were designated as the temperature at which the heat capacity 




3.2.7. Proteolytic Digestion  
 Control and photo-irradiated mAbZ were diluted to 10 mg/ml in 50 mM NH4+CO3-, pH 8.2. The 
diluted protein solutions were denatured with 3 M guanidine hydrochloride (in 50 mM  NH4+CO3), 
and disulfide bonds were reduced with 5 mM BMS (in ACN) at 37 °C for 1 h. The reduced samples 
were then alkylated with 25 mM IAA and further incubated at 37 °C for 1 h, diluted with 100 µl 
of 50 mM NH4+CO3-, and dialyzed in 50 mM NH4+CO3- for 1 h in a D-Tube™ Dialyzer Maxi 
(MWCO 3.5 kDa) at room temperature. The reduced and alkylated protein solutions were digested 
with 9 µl of 0.1 mg/ml trypsin/LysC overnight at 37 °C. The digestion of protein was stopped by 
addition of 10 µl of FA:H2O (0.1:0.9, v:v). The solution of the tryptic peptides was stored at -80 
°C until further HPLC-MS analysis. 
3.2.8.  UV-Visible Absorption Spectroscopy 
The absorbance spectra of control and photo-irradiated samples were collected on an Agilent 8453 
UV−visible spectrophotometer (Agilent Technologies, Santa Clara, CA) equipped with a 
photodiode array detector. The initial concentrated samples of 150 mg/ml mAbZ were diluted to 
10 mg/ml in either NaAc or His/Lys buffer. The samples were placed in 1 cm path length quartz 
cuvettes. UV-visible absorbance spectra of the samples were collected from 200 nm to 800 nm 
and the corresponding buffers were used as blanks. Second derivative spectra were obtained using 
a second order Savitizky-Golay smoothing filter.  
3.2.9. Reverse Phase-High-Performance Liquid Chromatography 
In order to fraction collect a specific photoproduct of NATA (i.e., NATA-33), we employed RP-




photoproduct were separated using a Vydac® 218TP54 protein and peptide C18 column (4.6 mm 
i.d. x 250 mm, 5 µm particle size, and 300 Å pore size) (Alltech Associates Inc, Deerfield, IL), 
which was maintained at 35 °C in a column heater. Aliquots of 10 µl of photo-irradiated NATA 
samples were injected onto the column and eluted with the following gradient of mobile phase A, 
(water with 0.1% TFA) and B (acetonitrile with 0.1% TFA) at a flow rate of 1 ml/min: composition 
of 97% A and 3% B was held for 5 min; the composition ranged linearly to 70% A and 30% B 
within 2 min, and subsequently changed linearly to 50% A and 50 % B within 3 min. To wash the 
column, 5% A and 95% B were employed for 2 min before the column was re-equilibrated to 97% 
A and 3% B for 6 min. The total run time was 20 min.  
3.2.10. NanoAcquity HPLC Electrospray ionization Q-tof MS  and HPLC-MS/MS analysis 
The proteolytic peptides of mAbZ and NATA and its photoproducts were analyzed on a Xevo-G2 
Qtof tandem mass spectrometer (Waters Corporation, Milford, MA), equipped with nanoAcquity 
Ultra Performance Liquid Chromatography system (Waters Corporation, Milford, MA). The 
proteolytic peptides (2.5 μl) were injected onto a Symmetry® C18 Waters trap column (2G-V/M 
Trap; 180 μm x 200 mm, 5 μm particle size, and 100 Å pore size) at a flow rate of 4 µl/min for 3 
min with the mobile phase composed of 97% A and 3% B. Mobile phase A and mobile phase B 
containing Optima® water with 0.1% FA and Optima® ACN with 0.1% FA, respectively. After 3 
min, the samples were directed to an analytical nanoAcquity ultra performance Waters peptide 
CSH ™ C18 column, (75 μm x 250 mm, 1.7 μm particle size, and 130 Å pore size) at a flow rate 
of 0.3 µl/min, maintained at 40 °C in a column heater. The initial gradient started with 97% mobile 
phase A and 3% mobile phase B, and the composition to 65% A and 35% B within 50 min. 




at this composition for an additional 10 min to wash the column. The solvent composition was 
reverted to the initial composition of 97% A and 3% B, and re-equilibrated for 32 min.  
For electrospray MS the source temperature was set at 100 °C. The instrument was operated in  a 
positive mode and the mass analyzer allowed the mass range from 150-2000 Da. The capillary 
voltage was set at 2.7 kV. The non-fragmented peptides were passed through a collision cell at 5 
eV, and the peptides were fragmented by ramping the collision cell energies between 18 eV and 
45 eV. The data were collected in the MSE mode. The HPLC-MS was operated, and data analyses 
were done with the Masslynx v.4.1 software. The data were plotted with the GraphPad Prism 7 
software.  
3.2.11. Nuclear Magnetic Resonance 
NATA and NATA-33 were dissolved in DMSO-d6 and transferred to a 5 mm Shigemi® tube 
(Wilmad Lab Glass, Vineland, NJ).  NMR spectra were collected on a Bruker AVIII 500 MHz 
instrument, equipped with a dual carbon/proton (CPBBFO) cryoprobe, at a sample temperature of 
25° C. All data were recorded with DMSO as the reference standard. The 1H-NMR spectrum was 
acquired with 256 scans at a spectrometer frequency of 500.19 MHz. The 13C-NMR spectrum was 
acquired with 66k scans at a spectrometer frequency of 125.79 MHz. The HSQC experiment was 
acquired with 32 scans, with 1024 points in the 1H dimension and 256 increments in the 13C 
dimension.  The spectral width was 14 and 180 for the 1H and 13C dimensions, respectively.  The 
relaxation delay was 2 seconds. 
3.3. Results 
Following exposure to visible light up to 8 h (1.44 W.h/m2) in NaAc or His/Lys buffer, mAbZ was 




3.3.1. Physical stability: studies on conformation and aggregation of mAbZ 
The aggregation propensity of control and photo-irradiated mAbZ was monitored by SDS-PAGE 
and SEC. Non-reducing SDS-PAGE shows a major band at around 150 kDa for mAbZ in both 
NaAc and His/Lys buffer (Fig. 1A). A low intensity band around 75 kDa suggests some half 
antibody formation, likely via cleavage of interchain disulfide bridges. Photo-irradiation with 
visible light for up to 8 h results in the formation of a higher molecular band in NaAc buffer, but 
to a significantly lower extent in His/Lys buffer (e.g., lanes 5 and 10, Fig. 1A). A higher molecular 
weight band (between 100 and 150 kDa) is also visible after 8 h photo-irradiation with visible light 
in NaAc when analyzed with reducing SDS-PAGE (Fig. 1B, lane 5). This suggests that some 
higher molecular weight species are generated via covalent bond formation, but not disulfides.  
These observations were corroborated by SEC (Fig. 2). Photo-irradiation with visible light induced 
the formation of dimers and HMWS in both buffers, where the yields of dimers and HMWS was 
two-fold higher in NaAc as compared to His/Lys buffer, ~7% of monomer was lost and ~3.5% 
dimer and ~3.5% HMWS were formed after 8 h light exposure (Fig. 2B). In comparison, in NaAc 
buffer, 15% of monomer was lost after 8 h of light exposure, which was accompanied by 6% dimer 
and 9% HMWS (Fig. 2B). 
In order to evaluate whether transition of metals played a role in the aggregation of mAbZ, a mAbZ 
formulation in NaAc buffer was spiked with 5 mM EDTA and photo-irradiated for 4 h. The yields 
of monomer loss and aggregates (dimers and HMWS) were similar for mAbZ formulated in NaAc 
buffer in the absence and presence of EDTA (Fig. S1). This indicates metals do not play a role in 
aggregation formation. On the other hand, when 10 mM His were added to mAbZ formulated in 




Because of the significant aggregation of mAbZ especially in NaAc buffer, we monitored the 
conformation stability of control and photo-irradiated mAbZ in both NaAc and His/Lys buffer by 
differential scanning calorimetry (DSC) (Fig. 3). The thermograms (Fig. 3A) of all samples were 
deconvoluted to provide Tm1, Tm2, and Tonset. Control mAbZ in both buffers displayed similar 
Tm1, whereas the Tm1 of mAbZ photo-irradiated in NaAc buffer decreased by about 0.5 °C after 
8 h exposure to visible light (Fig. 3BI). Instead, the Tm1 of mAbZ photo-irradiated in His/Lys 
buffer did not change upon light exposure (Fig. 3BI). For control, the Tm2 of mAbZ was higher 
in His/Lys buffer as compared to NaAc buffer (Fig. 3BII). We observed no significant change of 
Tm2 after light exposure for 8 h. However, Tonset decreased by 1 °C in NaAc buffer, whereas it 
decreased by 2 °C after 8 h visible light exposure in His/Lys buffer (Fig. 3BIII). However, as we 
did not observe large changes of the Tm1 and Tm2 values as a result of photo-irradiation, these 
data indicate that the tertiary structure of mAbZ did not undergo major changes.  
3.3.2. Oxidation of Met and Trp 
The proteolytic digests of control and photo-irradiated mAbZ were analyzed by HPLC-MS. The 
peak areas containing oxidized Met and Trp residues were calculated, and normalized by use of 
the proteolytic peptide, SLSLSLGK, which remained stable under our experimental conditions. 
There are six Met residues present in the heavy chain and none in the light chain of mAbZ. We 
observed the light-induced oxidation of Met to methionine sulfoxide (MetO) at positions 254, 360, 
and 430, where the yield of MetO increased with the duration of light exposure in both buffers, 
NaAc and His/Lys (Fig. 4A and 4C);  however, higher yields of MetO were observed in NaAc 
buffer. The light chain of mAbZ contains four Trp residues, out of which only the Trp at position 
90 (W90) was oxidized forming hydroxy tryptophan (OH-Trp) (Fig. 4B and 4D). The yields of 




irradiation time of 8 h.  We also observed NFK formation at position 90, but only by MS analysis; 
the yields were too low for MS/MS identification.  
3.3.3. Formation of chromophoric photoproducts in mAbZ and NATA 
After light exposure of up to 8 h, mAbZ formulated in NaAc buffer exhibited a color change from 
clear to yellow (Fig. 5A). In contrast, mAbZ formulated in His/Lys buffer did not display a 
significant color change after visible light exposure (Fig. 5B). By comparison of the UV-visible 
absorption spectra of control and photo-irradiated mAbZ in NaAc buffer, we observed an increase 
of the absorbance in the visible region with a λmax = ~450 nm (Fig. 6A). Importantly, visible light 
photo-irradiation of NATA in NaAc buffer (50 mM, pH 5.50) for 6 h resulted in a similar 
absorbance around λmax = ~450 nm (Fig. 6B). Second derivative UV/Vis spectroscopy of mAbZ 
and NATA confirmed that indeed identical product was generated in both experiments (Fig. 6C). 
When we expanded the light exposure of NATA in NaAc buffer to 24 h, a yellow color was 
observed (Fig. 7). Instead, when NATA was photo-irradiated in His/Lys buffer, a light brown color 
was observed, which could originate from degradation product of either His36 or Trp17, or both.  
Control and NATA photo-irradiated in both NaAc and His/Lys buffers were analyzed by RP-
HPLC and monitored at 300 or 400 nm. When exposed to visible light for up to 24 h, NATA 
converted into a number of products, monitored at 300 nm (Fig. 8AI and 8BI), where the individual 
yields increased with the duration of photo-irradiation; in general higher yields of photoproduct 
were observed in NaAc as compared to His/Lys buffer. We detected the formation of OH-Trp, 
NATA+14, Kyn, and NFK, eluting at tR = 6.95, 7.35, 7.70, and 7.85 min, respectively, before the 
unmodified NATA (tR = 8.75 min) (Fig. 8A-I and 8B-I). In addition, when the photoproducts were 




8A-II), and one peak for NATA photo-irradiated in His/Lys buffer (Fig. 8B-II). At tR = 7.85 min, 
we detected the formation of Kyn; however, a peak at tR = 11.7 min, containing NATA-33 was 
only observed in NaAc buffer. This peak was fraction-collected and analyzed by HPLC-MS. The 
HPLC-MS analysis revealed a molecular ion with m/z 213.09 (z = 1) (Fig. S2), corresponding to 
a loss of 33 Da from NATA (m/z 246.15, z = 1).  
The 13C-NMR spectrum of NATA-33 in DMSO-d6 (Fig. 9A) displayed 15 peaks with chemical 
shift at 1.25, 29.11, 40.00, 98.49, 103.57, 116.10, 125.48, 128.08, 129.03, 133.80, 142.06, 147.5, 
148.36, 149.06, and 180.39 ppm. The peaks at 1.25 and 116.10 ppm may correspond to the residual 
ACN left after drying, and the peak at 40.00 ppm corresponds to the carbons on DMSO-d6. The 
remainder of the signal were utilized for structural elucidation of NATA-33. A proposed structure, 
P1, is shown in Chart 1. The 1H-NMR of NATA-33 is shown in Fig. 9B.  Predictions for chemical 
shifts were made with MesoNova, nmrdb.org, and ChemDraw software for structure P1, shown in 
Table 1, 1H-13C Heteronuclear Single Quantum Correlation (HSQC) correlations are shown in 
Fig. S3, carbons at 98.49, 103.57, 116.1, 125.48, 128.08, and 129.03 correlate to 6.37, 6.38, 7.50, 
7.40, 7.47, and 7.71, respectively.  
HPLC-MS/MS analysis of NATA-33 was performed in the data dependent acquisition (DDA) 
mode (Fig. 10). The proposed structure P1 would be consistent with the fragmentation pattern as 
in Fig. 10, displaying a molecular ion with m/z 213.09 (z =1), which corresponds to the parent ion 
of P1. The loss of -CO gives the fragment with m/z 185.09 (z = 1). Either the ion with m/z 185.09 
can lose -27 Da (H3NO), or the molecular ion of P1 can lose 55 Da (C2HNO) to give a fragment 
with m/z 158.08 (z = 1). The loss of H2O and CO from m/z 158.08 give an ion with m/z 144.06 
and 130.08, respectively. A fragment containing an indole ring is observed with m/z 118.08 (z = 




MS/MS analysis of unmodified NATA, NATA-33 does not contain m/z 201.12 (z = 1), which 
corresponds to an intact N-terminus of NATA (Fig. S4), suggesting that NATA-33 may be 
generated through loss of the N-terminus of NATA. The combination of NMR and HPLC-NMR 
data fits structure P1. However, we also considered other possible structures of NATA-33  (P2 
and P3a or its isomers) shown in Chart 1, which will be discussed below.  
3.4. Discussion 
3.4.1. Aggregation, conformational changes, and oxidation of mAbZ 
Highly concentrated mAbZ was formulated either in NaAc and His/Lys buffer at pH 5.50. For 
photostability testing, mAbZ formulated in either buffer was exposed to visible light up to 8 h, 
resulting in the formation of dimers and HMWS (Fig. 1). Notably, mAbZ in NaAc buffer 
(containing NaCl) generated more aggregates as compared to His/Lys buffer.  The addition of 
EDTA had no effect on aggregation. On the other hand, the addition of His reduced HMWS 
formation. His residue can interact with aromatic residues8 and minimize self-association. The 
mAbZ formulation in His/Lys buffer contains additional Lys, which also reduces viscosity or self-
association of mAbs via electrostatic interactions.8, 37-38 The overall extent of light-induced 
oxidation rate of Met (254), Met (360), and Met (430) in the heavy chain and W(90) in the light 
chain of mAbZ was higher in NaAc buffer as compared to His/Lys buffer. While degradation 
products of His can act as photosensitizer,36 His also acts as a scavenger for reactive oxygen 
species such as singlet oxygen or hydroxyl radical.39  
3.4.2.  Formation of chromophoric photoproducts from mAbZ and NATA  
Interestingly, when the colorless mAbZ in either NaAc or His/Lys formulation was exposed to 




spectrum with λmax = ~450 nm (Fig. 6). Li et al. reported that photoproducts of Trp residues such 
as OH-Trp, NFK, and Kyn, in the variable domain of mAbZ are sources of color change.4 
However, these photoproducts have absorbance maxima at 300 nm, 318 nm, and 360 nm, 
respectively,23, 40-41 and cannot rationalize the absorption maximum around 450 nm. Therefore, we 
hypothesized that the absorption around 450 nm originated from a different tryptophan-derived 
oxidation product, and selected a Trp-containing model compound (NATA) for further 
characterization of this product.  
When NATA was exposed to visible light in NaAc buffer, a comparable chromophoric 
photoproduct was detected, and RP-HPLC analysis revealed a new product, NATA-33. After 
fraction collection and concentration of NATA-33, a brown color was observed (Fig. 8), similar 
to the color of a mAb exposed for 14 days to UV-visible light.4 Therefore, NATA and mAbZ may 
form similar chromophoric photoproduct even in the absence of PS80. The concentrated atypical 
peak generated from NATA was analyzed by HPLC-MS/MS and contained a product generated 
by loss of 33 Da from unmodified NATA. 1H- and 13C-NMR spectra were collected to elucidate 
the structure. Previous study by Dyer et al. on the photo-irradiation of wool proteins showed the 
formation of yellow β-carbolines (1,5-dihydro-β-carboline)  from Trp after through reaction with 
formaldehyde or α-keto acids.28 An analogous 1, 5-dihydro-β-carboline derivative derived from 
NATA is shown in the structure of product P2 (Chart 1). This proposed structure has chemical 
formula C13H13N2O+, displaying a molecular ion with m/z 213.09 (z = 1); however, the predictions 
of 1H- and 13C-NMR analysis of P2 do not correlate well with the actual 1H- and 13C-NMR spectra 
obtained for the chemical shift of NATA-33. Therefore, we evaluated alternative structures. The 
third proposed structure P3a may form via the mechanism shown in Scheme 1. Along with P3a, 




NMR spectra show a combination of these structures. The 1H- and 13C-NMR predictions for all 
isobaric species (Table S1 and S2) were calculated with the MesoNova, nmrdb.org, and 
ChemDraw software, and were correlated to the NMR spectra obtained from NATA-33 (Fig. 9). 
In the 13C-NMR predictions (Table S1), carbon at the position 5, 6, 7, and 8 may belong to the 
benzene ring and also correlate well with the observed peaks at 116.10, 125.48, 128.08, and 129.03 
ppm (Fig. 9A). Likewise, the carbons at position 14 and 15 may correspond to the carbonyl (180.39 
ppm) and methyl group (29.11 ppm), respectively. When predictor peaks of all the isobaric species 
are combined, further peaks in the obtained NMR can be assigned, such as the carbon at the 
position 9, which can be assigned to 133.80 ppm and carbons at positions 1, 2, 4, and 11, which 
can be assigned to 142.06, 147.5, 148.36, and 149.06 ppm.  Similarly, carbons at positions 10 and 
12 can be also be assigned to observed peaks at 98.49 and 103.57 ppm.  In addition, the predictor 
peaks of isobaric species (Table S2), can be assigned to the measured 1H-NMR spectrum (Fig. 
9B). Importantly, the proposed structures maintain at least one of the amides, suggesting that 
similar structures of mAbZ would remain bound to part of the protein framework. However, after 
8 h photo-irradiated ion with visible light the proteolytic digestion of mAbZ revealed no peptide 
peak with absorbance around 450 nm (Fig. S5). This may indicate that either the product is not 
peptide bound, or that a peptide-bound product was not recovered. In Fig. 9, we show a tentative 
product, P1, which is not peptide- or protein-bound. The predicted 13C resonances fit better with 
the observed 13C-NMR spectrum. However, the 1H-NMR spectrum does not correlate well with 
the predicted resonances.  
Here, we have reported a chromophoric product of a mAb after exposure to visible light. Using 
NATA as a model compound for Trp, the structure of the photoproduct was characterized by 




structures shown in Chart 1. Among the proposed structures, P3a and its isomers fit the NMR 
spectra best and is likely the prime candidate. Since the UV-Vis spectra of photo-irradiated mAb 
and NATA have similar absorbance, it is likely the degradation products in mAbZ attributed to 
modifications to Trp residues resulting in a product similar to P3a and its isomers. Such products 
are formed after cleavage of an amide bond, which can result in loss of biological activity of the 
protein as a whole. Since, photo-irradiated NATA in our experimental conditions and the mAb 
exposed to UV-visible light for 14 days shown by Li et al. have exhibited similar brown color, our 
results may explain one of the factors responsible for the color change of the mAb formulation. 
Here, the chromophoric product after exposure to visible light was observed from far below the 
ICH Q1B guideline. The observation of these products indicates that the photosensitive proteins 
must be protected not only from the UV light, but also from longer exposure to visible light. 
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3.6. Chart and Figures 








































Figure 1: SDS-Page analysis of mAbZ exposed to visible light for 0-8 h in NaAc buffer (lanes 2-
5) and in His/Lys buffer (lanes 7-10) Lane 1 and 6 show molecular makers (A) non-reducing gel, 








Figure 2: (A) SEC-HPLC of mAbZ in  NaAc and His/Lys buffer after photo-irradiation with visible 
light for 0 h (blue), 2 h (orange trace), 4 h (green trace), 6 h (red trace), and 8 h (purple trace). (B) 
Quantification of the peak areas of monomer, dimer, and HMWS of mAbZ in NaAc (red circles) 






















Figure 3: (A)Thermograms measured by DSC of mAbZ in NaAc and His/Lys buffer after photo-
irradiation with visible light between 0 and 8 h. (B) Tm1(B-I), Tm2 (B-II), and Tonset (B-III) of 
mAbZ after photo-irradiation with visible light between 0 and 8 h in NaAc (red-circles) and 
His/Lys buffer (blue-triangles). Samples were run in triplicate and error bars represent the standard 



















































Figure 4: Relative peak areas for MetO-containing peptides (A and C) and  OH-Trp-containing 
peptides (B and D) derived from proteolytic digestion of mAbZ in NaAc buffer (A and B) and 
His/Lys buffer (C and D) after photo-irradiation  for 0 h (blue), 2 h (red), 4 h (green), 6 h (purple), 
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Figure 6: Optical density of (A) mAbZ formulated in 50 mM NaAc buffer, pH 5.5, and (B) 10 mM 
NATA in 50 mM NaAc buffer, pH 5.5, after photo-irradiation with visible light for 8 h and 6 h, 





























Figure 7: (A) Visible light photo-irradiation of NATA leads to yellow colored solution in NaAc 
buffer and a brown colored solution in His/Lys. (B) UV-Vis spectra of NATA in NaAc and His/Lys 
buffer after 0 h (blue trace), 8 h (orange trace), 16 h (green trace), and 24 h (red trace) photo-
irradiation. The acetate solution exposed to 24 h photo-irradiation was diluted ten-fold and the 



































Figure 8: RP-HPLC chromatograms of NATA in NaAc buffer (A-I) monitored at 300 nm and (A-
II) at 400 nm, and in His/Lys buffer (B-I) monitored at 300 nm and (B-II) at 400 nm after photo-
irradiation with visible light for 0 h (blue trace), 8 h (orange trace), 16 h (green trace), and 24 h 






















Figure 9: (A) 13C-NMR spectra of NATA-33 and (B) 1H-NMR spectra of NATA-33, which were 
correlated with the 13C- and 1H-NMR predictions of P1 (refer to structure in Chart 1). See Table 1 




































3.7. Table and Scheme 




H spectra of P1 obtained from MesoNova, nmrdb.org, and ChemDraw. 


























































3.8. Supplementary Information 
 
 
Figure S1: (A) Quantification of loss of monomer and (B) formation of aggregates (contains 
dimer and HMWS) of mAbZ after exposure to visible light. mAbZ was either formulated in 






















































Figure S3: 1H-13C HSQC spectrum of NATA-33. Insert: Table with 1H and 13C HSQC 



























































Figure S5: RP-HPLC chromatograms of tryptic peptides of 8 h  photo-irradiated mAbZ, 



















Table S1: Predicted 13C spectra of  P3a, P3b, P3c, and P3d obtained from MesoNova, 





















Table S2: Predicted 1H peaks of P3a, P3b, P3c, and P3d obtained from MesoNova, nmrdb.org, 








 Chapter 4:  Cis/trans isomerization of unsaturated 
fatty acids in polysorbate 80 during light exposure 





Polysorbates are non-ionic surfactants and are frequently present in protein formulations in order 
to prevent aggregation or surface adsorption.1-3 They comprise highly heterogenous mixtures of 
fatty acid (FA) esters of polyoxyethylene (POE), polyoxyethylated sorbitan and polyoxyethylated 
isosorbide.1 The chemical stability of polysorbates is a concern where both oxidation and 
hydrolysis products can affect the integrity of pharmaceutical formulations.1-4 For example, 
proteins are sensitive to modification by peroxides5-6 and aldehydes/ketones7-8 generated through 
polysorbate oxidation. Moreover, free fatty acids (FFAs), generated via hydrolysis9-12 or 
oxidation,13 can generate particles, which may cause turbidity and/or protein 
adsorption/aggregation.  
A common hypothesis is that polysorbate degradation affects protein stability, i.e. that 
polysorbate degradation products trigger chemical and/or physical protein degradation. While 
there is good evidence supporting this hypothesis, recent studies also point to a role for protein in 
the generation of polysorbate degradation products. For example, it was reported that FFA 
generation in selected protein formulations can be the result of enzymatic hydrolysis, catalyzed 
by small levels of residual host cell proteins such as esterases and/or lipases.9-12 These results 
motivated us to evaluate additional potential protein-dependent pathways of polysorbate 
degradation. Considering the sensitivity of proteins to redox processes, reactive protein 
intermediates may play a more general role in the oxidative degradation of polysorbate. 
Here, we report that the light-exposure of polysorbate 80 (PS80)-containing formulations can 
induce the cis/trans isomerization of unsaturated FAs in polysorbate esters when proteins are 
present. These isomerization reactions likely result from reactions of thiyl radicals,14-19 which can 




cis/trans isomerization of mono- and polyunsaturated FAs comes from a series of mechanistic 
studies with isolated FAs and their methyl esters, phospholipids, micelles and vesicles.14-19 
Light exposure of a monoclonal antibody (mAb) can generate thiyl radicals (RS•) via various 
different pathways. First, the photo-ionization of a protein tryptophan (Trp) residue23 can lead to 
a hydrated electron, which efficiently reduces a protein disulfide bond to yield a protein thiyl 
radical and thiol (reactions 1 and 2).22 Photo-ionization processes of Trp have been observed at 
wavelengths > 300 nm,24-25 including typical pharmaceutical photostability testing in light 
chambers.26-27 
 
Concomitantly, this photo-ionization generates a tryptophan radical cation (Trp+•), and evidence 
for the formation of Trp+• during the light exposure of a mAb was provided by the detection of 
specific stable reaction products originating from Trp+• (such as Trp side chain cleavage 
products).27-28 In principle, protein thiyl radicals can react with unsaturated and polyunsaturated 





reactions may be restricted to polysorbate located outside micelles or directly associated with the 
protein. More efficient at inducing the cis/trans isomerization of unsaturated FAs, especially when 
located in micelles, would be small, lipophilic thiyl radicals such as e.g. the sulfhydryl radical 
(HS•) 18. The latter can be generated from cysteine thiyl radicals following 1,3-H-transfer and β-
elimination (reactions 3 and 4; only the side chain of cysteine is shown).29 
Because the cis/trans isomerization of mono- and polyunsaturated fatty acids is a chain reaction, 
even small quantities of thiyl radicals can lead to significant product yields, depending on the 
chain length of the reaction.30 In the following, we will demonstrate that cis/trans isomerization 
of unsaturated fatty acids proceeds upon light exposure of a formulation containing PS80 and (i) 
a monoclonal antibody, or (ii) a combination of N-acetyltryptophan amide (NATA) and 
glutathione disulfide (GSSG). The latter fact provides additional support for a thiyl radical-
mediated mechanism, as the system NATA/GSSG provides the two essential components for thiyl 
radical formation according to reactions (1) and (2), Trp and a disulfide, and represents a suitable 





4.2. Materials and Methods 
4.2.1. Materials 
Polysorbate 80 N.F. (J.T. Baker, product #4117-04, batch #0000190001) was purchased from 
Avantor (Radnor, PA). A monoclonal antibody (mAbZ) was provided by MedImmune 
(Gaithersburg, MD), formulated at 150 mg/ml mAbZ in the presence of 0.01% (w/w) PS80, 
sodium chloride, and sodium acetate. Sodium acetate (NaAc, product #S2889), glacial acetic acid 
(product #A38SI-212), oxidized L-Glutathione (GSSG, product #G4376), N-acetyl-L-
tryptophanamide (NATA, product #A6501), poly(ethylene glycol) (PEG, product #92897), 
linoleic acid (product #L1376), (9Z, 11E)-octadeca-9,11-dienoic acid (product #16413), (9E, 
11Z)-octadeca-9,11-dienoic acid (product #90983), (10E, 12Z)-octadeca-10,12-dienoic acid  
(product #04397), oleic acid (product #75090), elaidic acid (product #45089), and porcine 
esterase (product #1002633920, batch #SLBM0487V) were from Millipore Sigma (Burlington, 
MA). Ethyl acetate (product #E195-4) and borosilicate glass tubes (product #1496127) were from 
Fisher Scientific (Hampton, NH). Quartz glass tubes (product #8683) were from Ace Glass 
Incorporated (Vineland, NJ). 1,4-Dioxane (product #43167) was from Alfa Aesar (Tewksbury, 
MA). Ethanol (product #2701) was from Decon Laboratories (King of Prussia, PA). Water of 
ultra-pure quality (18.2 MΩ) was produced fresh with a WaterPro PS Polishing System 
(Labconco, Kansas City, MO). 
4.2.2. Photo-irradiation 
Photo-irradiation was performed in either quartz (λ= 254 nm) or borosilicate test tubes (all other 
conditions; wavelength cut off < 295 nm) under air atmosphere in a Rayonet Photoreactor (RPR-




following lamps (The Southern New England Ultraviolet Company, Branford, CT): RPR-2537A 
(λ= 254 nm), RPR-3000A (λmax = 305 nm; emission spectrum between 265 and 340 nm, RPR-
3500A (λmax = 350 nm, emission spectrum between 305 and 416 nm), or RPR-4190A (λmax = 419 
nm, emission spectrum between 390 and 475 nm). Actinometry was performed with the 
iodide/iodate actinometer31 for the RPR-2537A lamps, and the ferrioxalate actinometer32-34 for 
the RPR-3000A, RPR-3500A, and RPR-4190A lamps. In general, photon fluxes for all 
experimental conditions were < 4x10-8 Einstein/s (depending on sample volume). Based on the 
used sample volumes and test-tube geometries, our conditions correspond to light intensities of < 
40 W.h/m2 for 1 h photo-irradiations at λ = 254 nm and < 25 W.h/m2 for 1 h photo-irradiations at 
λmax = 305, 350 and 419 nm§, i.e. < 20% and < 12.5%, respectively, of the minimal intensity (200 
W.h/m2) recommended for UV photostability testing by the ICH guideline ICH Q1B.35 A critical 
assessment of the ICH Q1B guideline is given in the commentary by Baertschi et al.36 The authors 
provide typical UV-A light intensities for indoor lighting with window-filtered daylight at home 
and in the clinic (17 W/m2). Our light exposures of  < 25 W.h/m2 at λmax = 305, 350 and 419 nm 
would correspond to ca. 1-2 h exposure to indoor lighting at home or in the clinic.36 
4.2.3. Photo-irradiation of mAbZ formulations containing 0.01% PS80 
 Aliquots of 500 µl containing the mAbZ formulations containing 0.01% (w/w) were photo-
irradiated for 1 h with 4 lamps using the glassware/lamp type combinations described above.  To 
separate protein from PS80, the protein was precipitated with 900 µl cold ethanol by incubation 
at -20 °C for 1 h. The mAbZ pellet was separated from PS80 by centrifugation for 30 min at 
14,000 rpm (16,900g) at 4 °C. The supernatant was recovered and dried in a CentriVap 




in 100 µl of a 50/50 (v/v) ethanol/water mixture and vortexed to yield a PS80 concentration of 
0.01% (w/w) for liquid chromatography-mass spectrometry (LC-MS) analysis. As controls, 
aliquots of the mAbZ formulations were wrapped in aluminum foil and subsequently subjected 
to the same procedures of sample preparation. 
4.2.4. Photo-irradiation of spiked mAbZ formulations containing 0.2% PS80 
PS80 was spiked into the mAbZ formulation (see above) to bring the PS80 concentration to 0.2% 
(w/w). Aliquots of 200 µl were photo-irradiated at either λ = 254 nm or λmax = 305 nm as described 
above for 1 h with 4 lamps, respectively. Precipitation and supernatant drying were performed as 
described above.  Each dried sample was then dissolved in 1 ml of a 50/50 (v/v) ethanol/water 
solution and vortexed to yield a PS80 concentration of 0.02% (w/w) for LC-MS analysis.  As 
controls, aliquots of the mAbZ formulations were wrapped in aluminum foil and subsequently 
subjected to the same procedures of sample preparation. 
4.2.5. Photo-irradiation of model peptide formulations containing 0.01% and 0.2% PS80 
The combination of Trp and disulfide is the basic entity amenable to light-induced generation of 
thiyl radicals according to reactions 1 and 2, and is a suitable model for Trp/disulfide triads26 in 
monoclonal antibodies. Stock solutions containing 10 mM GSSG and/or 10 mM NATA were 
prepared in 20 or 50 mM NaAc buffer (pH 5.5). An initial stock of 10% (w/w) PS80 in water was 
diluted to 0.02% and 0.4% (w/w) in 20 or 50 mM NaAc buffer (pH 5.5), and mixed 1:1 with the 
stock solutions containing GSSG, NATA, or both, to bring the final concentration of GSSG and/or 
NATA to 5 mM, and PS80 to either 0.01% or 0.2% (w/w). Aliquots of 400 µl were photo-
irradiated at λmax = 305 nm as described above for 1 h with 4 lamps. To ensure comparability, 




above.  Each dried sample was then dissolved in 100 µl (model peptide formulations with 0.01% 
PS80 (w/w)) or 1 ml (model peptide formulations with 0.2% PS80 (w/w)) of a 50/50 (v/v) 
ethanol/water solution and vortexed to yield PS80 concentrations of 0.01% and 0.02% (w/w) for 
LC-MS analysis, respectively. As dark controls, reaction mixtures were wrapped in aluminum 
foil and exposed to 1 h photo-irradiation in the Rayonet reactor. In addition, we confirmed that 
the exposure of the reaction mixtures to elevated temperatures (40oC, 2 days) did not result in 
cis/trans isomerization.  
4.2.6. Photo-irradiation of PS80 in the absence of mAbZ and model peptides 
A stock solution of 10% PS80 (w/w) was prepared in water. The PS80 stock solution was diluted 
to either 0.01% or 0.2% (w/w) in either 50 or 20 mM NaAc buffer (pH 5.5). Aliquots of 500 µl 
were photo-irradiated separately using the glassware / lamp type combinations described above 
for 1 h with 4 lamps, respectively. We subsequently subjected these samples to the same 
precipitation and drying procedures as described above for the removal of mAbZ from samples 
containing PS80. Each dried sample was then dissolved in 100 µl (formulations with 0.01% PS80 
(w/w)) or 1 ml (formulations with 0.2% PS80 (w/w)) of a 50/50 (v/v) ethanol/water solution and 
vortexed to yield PS80 concentrations of 0.01% and 0.02% (w/w) for LC-MS analysis, 
respectively.  As dark controls, reaction mixtures were wrapped in aluminum foil and exposed to 
1 h photo-irradiation in the Rayonet reactor.  
4.2.7. Generation of FFAs from 0.01% and 0.2% PS80 with porcine esterase 
FFA generation for analysis from 0.01% (w/w) PS80 solutions required pre-concentration. To 
concentrate a sample from 0.01% to approximately 0.05% PS80, 100 µl aliquots from a 500 µl 




Then, 100 µl of 10 mM phosphate buffer (pH 7.2) was added to the first of the 5 vials, and 
subsequently transferred from one vial to the next to recover PS80. An aliquot of 2 µl of porcine 
esterase (10 units; 24 mg esterase/ml; 208 units/mg protein) was added to this concentrated PS80 
solution and incubated at 37 °C for 1 h (during 1 h esterase reaction, ca. 27% free oleic acid was 
generated, mainly from the hydrolysis of oleic acid monoesters, consistent with earlier data10). 
The esterase was precipitated with cold ethanol and the supernatant dried. The dried sample was 
dissolved in 50 µl ethanol for LC-MS analysis. The recovery of FFAs was >60%.   The dark 
control samples were wrapped in aluminum, stored at room temperature and subjected to the same 
procedures to obtain FFAs. No pre-concentration step was required for the generation and analysis 
of FFAs from 0.2% (w/w) PS80 solutions. They were directly subjected to precipitation and 
drying. However, two precipitation methods were compared using either borosilicate glass or 
Eppendorf tubes. Interestingly, higher levels of baseline FFA oxidation products were observed 
after precipitation in borosilicate glass; therefore, precipitation was conducted in Eppendorf tubes 
in order to monitor photo-chemically generated FFA oxidation products. 
4.2.8. HPLC-MS analysis of PS80 
The PS80 components and their degradants were analyzed by electrospray ionization (ESI) mass 
spectrometry on a Waters Q-TOF Premier mass spectrometer (Milford, MA, USA) coupled to a 
Waters ACQUITY UPLC system (Milford, MA, USA). The electrospray ionization source was 
maintained at 120oC, and the capillary voltage set to 2.8 kV. Data were collected in the MSE mode 
(first function) at a mass range of 150-2000 Da. The mass spectrometer was operated in the 





All analytes were separated on a Prevail™ C18 column (Grace, Deerfield, IL; 150 mm × 2.1 mm, 
300 Å pore-size, 3.0 µm particle size). The column temperature was maintained at 40 oC and 
either 10 µl of 0.01% (w/w) PS80 or 5 µl of 0.02% (w/w) PS80 (i.e. 1 µg PS80 based on the initial 
sample concentration) were injected onto the column and eluted at a flow rate of 0.4 ml/min. Four 
mobile phases, A-D, were used to elute PS80 from the column. Mobile phase A contained 2 mM 
ammonium formate, and 0.08% formi°acid in water, mobile phase B contained a 7:3 (v/v) 
acetonitrile/methanol solution with 0.08% formic acid, mobile phase C consisted of isopropanol, 
and mobile phase D contained a 1:9 (v/v) 1,4-dioxane/acetone solution, respectively. Separation 
of PS80 components was achieved with the following gradient (all changes linear): initially, the 
mobile phase composition was 40% A and 60% B, within 15 min the composition was changed 
to 1% A and 99 % B, within the next 5 minthe composition was changed to 1% A, 94% B, and 
5% C, within the next 1 min the composition was changed to 1% A, 90% B, and 9% C and held 
for 2 min, within the next 1 min the composition was changed to 1% A and 99% D and held for 
3 min (wash phase), within the next 1 min the composition was changed back to 40% A and 60% 
B and the column was re-equilibrated for 7 min. 
4.2.9. HPLC-MS analysis of FFAs 
FFAs were analyzed by electrospray ionization mass spectrometry on the same instrument 
described above. The column, Masslynx software, and instrument settings remained identical 
except that the instrument was operated in the negative ion mode and data were collected in the 
MSE mode (first function) at a mass range of 100-2000 Da.  10 µl aliquots were injected onto the 
column and eluted at a flow rate of 0.4 ml/min. Three mobile phases, A-C as described above, 
were used to elute FFAs from the column. Separation of FFAs was achieved with the following 




within 1 min the composition was changed to 22% A and 78 % B, within the next 11 min the 
composition was changed to 16% A, 80% B, and 4% C, within the next 1 min the composition 
was changed to 75% B and 25% C, within the next 2 min the composition was changed to 10% 
A, 40% B, and 50%C, within the next 1 min the composition was changed back to 40% A and 
60% B, and the column was re-equilibrated for 4 min. 
4.2.10. Sample preparation for Raman Fourier transform infrared (FTIR) spectroscopy 
Two sets of samples were prepared for Raman and FTIR spectroscopy: (i) 5 mM GSSG, 5 mM 
NATA, 0.2% (w/w) PS80 in 20 mM NaAc (pH 5.5); (ii) 147 mg/ml mAbZ formulated with PS80 
and NaAc. A dark control and a photo-irradiated sample were produced for each sample 
formulation. Aliquots of 3 ml were photo-irradiated at λmax = 305 nm as described above for 1h 
with 4 lamps. 
PS80 extraction for each sample was performed using a 50/50 (v/v) ethyl acetate/1,4-dioxane 
solution (“organic phase”)$: equal volumes of sample and organic phase were mixed by pipetting 
and centrifuged at 4500 rpm and 4 °C for 10 min. The organic phase was then collected into a 
fresh borosilicate tube and the procedure repeated two more times. The collected organic phases 
were dried in a CentriVap for 2 h at room temperature. Each dried sample was dissolved in ethanol 
to yield a 50 mg/ml PS80 solution based on initial PS80 concentrations. Reference substances 
(oleic acid, elaidic acid, linoleic acid, and the conjugated octadecadienoic acids) were dissolved 
or diluted in ethanol to yield final concentrations of 50 mg/ml. Except during photo-irradiation, 




4.2.11. Raman and FTIR Spectroscopy 
Raman spectra of sample and reference solutions were obtained using a Zetasizer Nano ZS Helix 
(Malvern Panalytical, Malvern, United Kingdom) connected to a Kaiser Raman RxN1 
spectrometer (Kaiser Optical Systems, Ann Arbor, MI). The spectrometer includes a 785 nm laser 
having a maximum power output of 400 mW. For each measurement, 20 replicates of 10 s 
exposure intervals were recorded from 100 – 1890 cm-1. The sample cell was set to 25 °C. Raman 
spectra were background subtracted, baseline offset corrected, and normalized. Second derivative 
spectra were calculated following Savitzky-Golay smoothing with a 13-point 3rd order 
polynomial. 
FTIR spectra of sample and reference solutions were obtained using a Bruker Tensor 27 FTIR 
spectrometer fitted with a Bio-ATR cell (Bruker, Billerica, MA) set to 25 °C. Fir each 
measurement, 256 scans were recorded from 800 – 4000 cm-1 at a resolution of 4 cm-1. OPUS 6.5 
(Bruker) was used for atmospheric correction and baseline fitting. 
4.3. Results 
4.3.1. Oleic acid 
When we exposed a formulation of 150 mg/mL mAbZ in the presence of 0.01% (w/w) PS80, 
NaCl, and NaAc to 1 h photo-irradiation at λmax = 305 nm, some significant changes in PS80 
composition were noted by LC-MS analysis (Figure 1A and 1B). In controls (Figure 1A), the 
peaks with tR = 11.23 and 12.65 min represent POE sorbitan oleic acid and POE oleic acid, 
respectively. Notably, photo-irradiation leads to a change in peak shape for POE sorbitan oleic 
acid (Figure 1B; peak I), and a new peak with tR = 12.84 min (Figure 1B; peak IIb), eluting 




= 12.84 min contains a product which is isobaric with POE oleic acid, suggesting the generation 
of isomers. None of these changes appear when 0.01% (w/w) PS80 in either 20 mM or 50 mM 
NaAc (pH 5.5) is photo-irradiated in the absence of mAbZ (not shown). Figure 2 compares the 
LC-MS peaks representatively for the extracted signal of m/z 828.60 (z = +1, [M+NH4] of a 
control formulation (Figure 2A) and a formulation photo-irradiated for 1 h at λ = 254nm (Figure 
2B) and λmax = 305 nm (Figure 2C) to further illustrate the formation of such isobaric species. 
Here, m/z 828.60 represents a POE oleic acid containing 12 ethylene oxide (EO) units, POE (12) 
oleic acid. Analogous analyses were made for POE oleic acid components; these contain between 
6 and 22 EO units and make up the envelope of all POE oleic acid species present in the peaks 
eluting with tR = 12.56 and 12.84 min. The isobaric species with m/z 828.60 forms during photo-
irradiation for 1h at either λ = 254 nm and λmax = 305 nm, but not λmax = 350 nm (Figure 2D). 
However, during longer photo-irradiation times (up to 8 h; equivalent to < 200 W.h/m2) at λmax = 
350 nm, the isobaric species with m/z 828.60 is generated (Figure S1), indicating that near UV 
light is able to trigger the reactions leading to the formation of the isobaric species. In contrast, 
visible light photo-irradiation at λmax = 419 nm for up to 12 h did not generate significant yields 
of the isobaric reaction product. A similar analysis was also made for POE sorbitan oleic acid 
components, were photo-irradiation at λmax = 305 nm resulted in the generation of isobaric 
species. This is shown representatively for POE (26) sorbitan oleic acid in Figure S2, where the 
signal of m/z 804.56 (z = +2, [M+2NH4]) revealed a shoulder after photo-irradiation. 
The formation of a reaction product isobaric with POE oleic acid suggests that oleic acid may 
undergo cis/trans isomerization to elaidic acid. In order to evaluate this possibility, we subjected 
reaction mixtures to porcine esterase to liberate FFAs. Figure 3 compares formulations containing 




irradiation at λmax = 305 nm. Clearly, elaidic acid is generated during photo-irradiation only in 
the presence of mAbZ, confirmed by spiking (0.01 mg/mL) with an authentic standard of elaidic 
acid (Figure S3). 
The conversion of oleic into elaidic acid is likely caused by intermediary thiyl radicals, which can 
be generated by photo-induced electron transfer from Trp to protein disulfide bonds22. In fact, 
mAbs contain Cys-Cys-Trp triads, which are exquisitely sensitive to photo-degradation26. Further 
experimental support for a role of photo-induced electron transfer from Trp to disulfides in the 
formation of elaidic acid was, therefore, acquired in a model system where final concentrations 
of 5 mM NATA and 5 mM GSSG were added to 0.01% (w/w) PS80 in 20 mM NaAc (pH 5.5). 
Photo-irradiation of this reaction mixture for 1h at λmax = 305 nm resulted in the generation of 
elaidic acid (Figure 3, panels C and D) when both GSSG and NATA were present but not in 
absence of either NATA or GSSG (Figure S4). Hence, thiyl radicals generated by the 
NATA/GSSG model system were able to induce cis/trans isomerization of oleic acid. This was 
confirmed by positive ion mode ESI-LC-MS showing the formation of isobaric products, e.g. 
representatively of POE (12) oleic acid. No isobaric species of POE (12) oleic acid was formed 
in the absence of either NATA or GSSG (Figure S5). Quantitation of the extent of cis/trans 
isomerization was achieved by two ways. First, POE oleic acid is reasonably well resolved from 
POE elaidic acid during HPLC-MS analysis, which allows for quantitation of ca. 70% POE oleic 
acid and 30 % POE elaidic acid after 1h photo-irradiation (with λmax = 305 nm) of PS80 
formulations containing mAbZ. POE sorbitan oleic acid and POE isosorbide oleic acid are less 
well resolved from their elaidic acid isomers, so that direct quantitation of cis/trans isomerization 
for these species by HPLC-MS analysis could not be achieved. However, the relative contents of 




ca. 90% oleic acid and 10% elaidic acid after 1h photo-irradiation (with λmax = 305 nm) of PS80 
formulations containing mAbZ. These data suggest that POE oleic acid is somehow more 
sensitive to cis/trans isomerization compared to POE sorbitan oleic acid and POE isosorbide oleic 
acid. 
4.3.2. Linoleic acid 
PS80 contains a significant fraction of linoleic acid, specified as < 18% by the European, the US, 
and the Japanese Pharmacopoeia3. While this content of <18% is lower compared to that of oleic 
acid (≥58%), the higher reactivity of linoleic acid as well as all polyunsaturated FAs towards 
oxidizing radicals37 makes linoleic acid a prominent target for oxidative degradation. With two 
isolated double bonds, separated by a bisallylic methylene group, linoleic acid is also a bona fide 
target for radical-induced isomerization16. By mass spectrometry analysis of marker ions for oleic 
and linoleic acid, we quantified the content of oleic acid as 75.1% in PS80 obtained directly from 
J.T.Baker (see Materials) and 64.6% in PS80 present in the MedImmune formulation of mAbZ. 
The content of linoleic acid was 14.4% in PS80 directly obtained from J.T. Baker and 7.3%, in 
PS80 present in the MedImmune formulation of mAbZ.   
The photo-irradiation (1 h at λmax = 305 nm) of a formulation containing 150 mg/mL mAbZ, 
0.01% (w/w) PS80, NaCl and NaAc generated isobaric species from linoleic acid. This is shown 
in Figure 4, where peaks IIa and IIb, contain isobaric species, representing POE sorbitan linoleic 
acid with 26 EO units, POE (26) sorbitan linoleate (m/z 803.56, z = +2, [M+2NH4]). Similar 
observations were made for POE (20-32) sorbitan linoleate. In Figure 4, peak V elutes closer to 
the diester species and represents most likely POE (20) sorbitan oleate/linoleate or POE (21) 




This is confirmed by the analysis of FFAs, shown in Figure 5A, where photo-irradiation of the 
formulation containing 150 mg/mL mAbZ  resulted in a change of the relative intensities of three 
isobaric peaks with m/z 279.22 (z = -1, [M-H]), representing linoleic acid and isomers of linoleic 
acid. Additional experiments were performed with 0.2% (w/w) of PS80, in order to increase the 
sensitivity of our analysis and relate our LC-MS data to Raman and FTIR spectroscopy (vide 
infra) which required higher PS80 concentrations. For these experiments, we purchased PS80 and 
spiked it into the original mAbZ formulation obtained from MedImmune. Figure 5B‡ compares 
non-irradiated controls with photo-irradiated (1 h at either λ = 254 nm or λmax = 305 nm) 
formulations after esterase digestion of the reaction mixtures. Again, extraction of the signal with 
m/z 279.22 (z = -1, [M-H]) resulted in three isobaric species, similar to the data in Figure 5A#. 
Specifically, photo-irradiation with λmax = 305 nm revealed an increased intensity of peaks eluting 
with tR = 8.44 min and tR = 9.66 min. Spiking with authentic standards (0.01 mg/mL) of (9Z, 
12Z)-octadeca-9,12-dienoic acid (linoleic acid), and conjugated linoleic acids (CLA), specifically 
(9Z, 11E)-octadeca-9,11-dienoic acid (rumenic acid), (9E, 11E)-octadeca-9,11-dienoic acid, and 
(10E, 12Z)-octadeca-10,12-dienoic acid, was performed to get a general idea on the elution times 
of geometric isomers of linoleic acid. To our surprise, linoleic acid ((9Z, 12Z)-octadeca-9,12-
dienoic acid; tR = 8.44 min) clearly represented only a minor component in the PS80 we purchased 
to spike into the MedImmune formulations. Instead a peak eluting with tR = 8.78 min, co-eluting 
with (9Z, 11E)-octadeca-9,11-dienoic acid (rumenic acid) and (10E, 12Z)-octadeca-10,12-
dienoic acid, represented the major component of PS80. Both, (9Z, 11E)-octadeca-9,11-dienoic 
acid (rumenic acid) and (10E, 12Z)-octadeca-10,12-dienoic acid can be generated from (9Z, 12Z)-
octadeca-9,12-dienoic acid (linoleic acid) by hydrogen abstraction from the bisallylic methylene 




into carbon-centered radicals at C-13 or C-9, hydrogen addition to which would yield (9Z, 11E)-
octadeca-9,11-dienoic acid (rumenic acid) and (10E, 12Z)-octadeca-10,12-dienoic acid, 
respectively (we note, that oxygen addition would yield peroxyl radicals and hydroperoxides, 
generating oxidation products; see below). Photo-irradiation with both λ = 254 nm and λmax = 
305 nm resulted in a slight increase of the peak representing linoleic acid but in significant growth 
of a peak with tR = 9.66 min, co-eluting with (9E, 11E)-octadeca-9,11-dienoic acid. A quantitative 
comparison of the changes of relative peak areas of the respective FA isomers during photo-
irradiation at λmax = 305 nm is shown in Figure 6. Noteworthy, in formulations containing 0.2% 
PS80 small changes are even observed during photo-irradiation in the absence of mAbZ; however, 
a significantly higher conversion of cis/trans or trans/cis conjugated FAs into trans/trans 
conjugated FAs is observed in the presence of mAbZ. 
4.3.3. Oxidation products 
The light exposure of formulations containing 150 mg/ml mAbZ, 0.01% (w/w) PS80, NaCl and 
NaAc, leads not only to cis/trans isomerization but also to the formation of oxidation products. 
Figure 7 shows data (m/z 313.24 (281.24+32); z = -1, [M-H]) representative for oleic acid with 
an addition of +32 atomic mass units (amu), consistent with hydroperoxide formation, and 
observed during FFA analysis after photo-irradiation and esterase hydrolysis of PS80. Figure 7A 
displays a baseline level of the signal with m/z 313.24 even in control PS80, where at least three 
isobaric components can be distinguished, eluting with tR = 2.74, 3.08 and 3.12 min. Considering 
that radical processes can theoretically introduce hydroperoxide groups at positions C-8, C-9, C-
10, and C-11, the chromatographic resolution of isobaric hydroperoxide products is expected. The 




a pronounced increase in the intensities of the isobaric signals with m/z 313.24, and thus is 
consistent with the photo-induced generation of radicals from oleic acid followed by the 
formation of hydroperoxides. 
4.3.4. The model system containing PS80, GSSG, and NATA 
Reactions 1 and 2 provide a facile mechanism for the generation of mAbZ thiyl radicals which 
can then induce the cis/trans isomerization and/or oxidation of unsaturated fatty acids. In order to 
further confirm the feasibility of this mechanism, a formulation containing 0.01% (w/w) PS80, 5 
mM GSSG, and 5 mM NATA in either 20 mM or 50 mM NaAc buffer (pH 5.5), was photo-
irradiated for 1 h at λmax = 305 nm. Under these conditions, we observed the conversion of oleic 
acid into elaidic acid (Figures 3C, 3D, and S2; see above) analogous to our results in the presence 
of mAbZ (Figures 3A and 3B). Furthermore, a significant loss of the signal representing (9Z, 
11E)-octadeca-9,11-dienoic acid (rumenic acid) and (10E, 12Z)-octadeca-10,12-dienoic acid was 
only in part accounted for by an increase in the signal for (9E, 11E)-octadeca-9,11-dienoic acid 
(Figure 8A and B). These unaccounted products are likely oxidation products. Consistent with 
this expectation, the photo-irradiation of 0.01% (w/w) PS80, 5 mM GSSG, and 5 mM NATA in 
20 mM NaAc buffer (pH 5.5) for 1 h at λmax = 305 nm yielded significant quantities of several 
oxidation products isobaric with linoleic acid +16 amu (Figure 8C) and a product isobaric with 
linoleic acid +32 amu, likely linoleic acid hydroperoxide (Figure 8D). 
4.3.5. Raman and FTIR Spectroscopy 
Second derivative Raman spectra of FFA reference solutions are displayed in Figure 9A. In 
general, due to the conjugated dienes, CLAs showed significantly stronger Raman scattering than 




at 1659.5 cm-1 while (9Z, 11E)-octadeca-9,11-dienoic acid and (10E, 12Z)-octadeca-10,12-
dienoic acid both revealed a peak at 1653.0 cm-1. Linoleic, oleic, and elaidic acids showed broad 
peaks at 1658.0 cm-1, 1655.0 cm-1, and 1669.0 cm-1, respectively. 
Second derivative Raman spectra of solutions containing either individual formulation 
components or complete formulations (control and photo-irradiated) are displayed in in Figure 
9B. All non-irradiated solutions (controls) containing PS80 showed a peak at 1653.5 cm-1. This 
peak clearly indicated the presence of (9Z, 11E)-octadeca-9,11-dienoic acid and/or (10E, 12Z)-
octadeca-10,12-dienoic acid; the shift to a slightly higher wavenumber with respect to the FFA 
reference solutions is possibly related to the presence of oleic and linoleic acid. Photo-irradiation 
of PS80 in presence GSSG and NATA or in presence of mAbZ had a strong effect on the FA 
composition. In both cases, a relative reduction of the peak intensity for (9Z, 11E)-octadeca-9,11-
dienoic acid and/or (10E, 12Z)-octadeca-10,12-dienoic acid and a relative increase of peak 
intensity for (9E, 11E)-octadeca-9,11-dienoic acid was observed. In contrast, photo-irradiation of 
PS80 alone resulted only in a minor loss of peak intensity at 1653.5 cm-1 and no additional peaks 
were observed. The peak at ~1620 cm-1 was attributed to the presence of NATA. Raman 
spectroscopy was found advantageous when analyzing CLAs in PS80 because the POE segment 
of a polysorbate molecule, which can be represented by PEG, displays no spectral features in the 
range from 1700 cm-1 to 1600 cm-1 (Figure 10C). No difference between a freshly prepared 5% 
PS80 (Figure 9C) solution in ethanol and the processed PS80 control (Figure 9B) was observed. 
FTIR spectra of FFA reference solutions are displayed in Figure 10A. (9E, 11E)-octadeca-9,11-
dienoic acid showed a peak at 988 cm-1 and elaidic acid, containing an isolated trans double bond, 
showed a peak at 968 cm-1. (9Z, 11E)-octadeca-9,11-dienoic acid (rumenic acid) and (10E, 12Z)-




((9Z, 12Z)-octadeca-9,12-dienoic acid) showed a broad peak at ~913 cm-1, while no characteristic 
peak was identified for oleic acid. These reference spectra are in good agreement with earlier 
reports38. FTIR spectra of solutions containing either individual formulation components or 
complete formulations (control and photo-irradiated) are displayed in Figure 10B. All solutions, 
except the ones prepared from buffer solutions in the absence of PS80, revealed peaks at ~986 
cm-1, ~950 cm-1, and ~915 cm-1. The peaks at ~986 cm-1 and ~950 cm-1 indicated a mixture of 
CLAs: The peak at ~986 cm-1 is located in between the reference peaks for (9E, 11E)-octadeca-
9,11-dienoic acid, and (9Z, 11E)-octadeca-9,11-dienoic acid and (10E, 12Z)-octadeca-10,12-
dienoic acid (984cm-1). The peak at ~950 cm-1 indicated the presence of (9Z, 11E)-octadeca-9,11-
dienoic acid and (10E, 12Z)-octadeca-10,12-dienoic acid. The peak at ~915 cm-1 indicated the 
presence of linoleic acid. However, the use of FTIR to assess PS80 has several limitations not 
encountered when using Raman spectroscopy as described above. First, FTIR assessment of a 5% 
solution of PS80 in ethanol showed very similar spectral features when compared to a saturated 
solution of PEG, representing the POE segment of PS80 (Figure 10C). The spectral features of 
the fatty acids are only observed after PS80 extraction, drying, and dissolution of the dried sample. 
One possible explanation is the limited solubility of PEG in ethanol when compared to PS80, 
meaning that extracted PS80 but not free POE readily dissolves after drying. In addition, the 
overlapping signals of the CLAs as well as signals from NATA and linoleic acid complicate a 
definite assignment beyond the statement that various CLA species are present. 
4.4. Discussion 
The oxidative degradation of polysorbate is a well-known phenomenon, usually attributed to 
oxidation processes induced by transition metal catalysis, reactive oxygen species, and/or light 




polysorbate degradation for the chemical and physical integrity of APIs such as therapeutic 
proteins. These include chemical modifications, e.g. the potential reactions of peroxides and 
aldehydes/ketones with proteins, and physical alterations, e.g. the generation of protein 
aggregates and/or particles1-3, 5-11, 39-40. In this chapter, we show that light-exposure of PS80-
containing formulations leads to cis/trans-isomerization of unsaturated FA components of PS80 
when a mAb is present, but not in its absence. This pathway likely involves the reductive cleavage 
of disulfide bonds by photo-induced electron transfer from Trp, generating thiyl radicals 
(reactions 1-4). This pathway was independently confirmed by light exposure of PS80 in the 
presence of the model system NATA/GSSG, which caused cis/trans isomerization of unsaturated 
fatty acids. Importantly, the photo-induced cis/trans isomerization occurred at wavelengths 
including near UV light, i.e. at wavelengths present in indoor fluorescent lighting. 
In 1959, Walling and Helmreich reported on the isomerization of olefins by thiyl radicals41. About 
40 years later, Chatgilialoglu, Ferreri and coworkers initiated a series of mechanistic studies on 
thiyl radical-induced isomerization of double bonds in mono- and polyunsaturated FAs 14-19, 
proceeding according to equilibria 5 and 6, where in tert-butanol at room temperature kaZ = 
1.6x105 M-1s-1, kaE = 2.9x10-1s-1, kfZ = 1.7x107 M-1s-1, and kfE = 1.6x108 M-1s-1 (RS• = 
HOCH2CH2S•)42. 
  
This cis/trans isomerization proceeds via a chain reaction, which is subject to retardation by 




bisallylic methylene groups such as present in mono- and polyunsaturated FAs. Such reactions 
lead to intermediary carbon-centered radicals, which, in the presence of oxygen, will convert into 
peroxyl radicals and ultimately FA hydroperoxides. Figure 7 shows representative data for the 
formation of oleic acid-derived products, which are +32 amu higher in mass, consistent with the 
formation of oleic acid hydroperoxides from PS80. Second, retardation can be achieved by the 
reaction of thiyl radicals with conjugated double bonds, such as shown by Graham et al. 43 for the 
cis /trans isomerization of 2-butene in the presence of 1,3-butadiene. The latter observation is 
relevant for our formulations, as our analysis of FFAs (Figures 5 and 6) shows that PS80 can 
contain significant amounts of FAs with conjugated double bonds such as e.g. (9Z, 11E)-
octadeca-9,11-dienoic acid (rumenic acid) and/or (10E, 12Z)-octadeca-10,12-dienoic acid. This 
observation, also confirmed by Raman spectroscopy, is consistent with earlier NMR data 
presented by Hvattum et al.44, which suggested that the majority of the C18:2 fatty acids in PS80 
contain conjugated double bonds. Photo-irradiation of formulations containing 150 mg/mL mAbZ 
together with PS80, NaCl and NaAc generated a product co-eluting with (9E, 11E)-octadeca-
9,11-dienoic acid (Figure 5), and it would be feasible to assume that thiyl radicals could convert 
(9Z, 11E)-octadeca-9,11-dienoic acid (rumenic acid) into (9E, 11E)-octadeca-9,11-dienoic acid. 
We note that different batches of PS80 can contain different amounts of linoleic acid and 
conjugated linoleic acids, as we observed when comparing PS80 obtained from J.T. Baker and 
PS80 present in the formulations containing mAbZ. We do not know to what extent these 
differences are caused by batch-to-batch variability or aging of PS80.  
The presence of fatty acids with conjugated double bonds has likely an inhibitory effect30 on the 
cis/trans isomerization reactions induced by light exposure of mAbZ and NATA/GSSG under our 




expected to be rather sensitive to oxidation. Kitaguchi et al. reported a linear relationship of rate 
constants for hydrogen abstraction by peroxyl radicals from polyunsaturated fatty acids 
depending on the number of bisallylic methylene groups45. Hydrogen abstraction from the 
bisallylic methylene groups leads to the formation of pentadienyl radicals. Linoleic acid contains 
two non-conjugated double bonds and one bisallylic methylene group. However, CLAs contain 
methylene groups on each site of the conjugated double bond system, where hydrogen abstraction 
would lead to the generation of pentadienyl radicals. Consequently, we expect that CLAs exhibit 
oxidation sensitivities comparable to that of linolenic acid, a highly oxidation-sensitive 
polyunsaturated fatty acid. Hence, despite their potential to retard cis/trans isomerization 
reactions, CLAs represent prominent targets for radical formation, and origins for oxidation 
reactions.  
The potential for radical-induced cis/trans isomerization of mono- and polyunsaturated fatty acids 
in PS80 is significant for the following reasons. First, the appearance of trans-FAs in 
formulations, either in polysorbate esters or FFAs, may serve as a probe for the intermediary 
generation of free radicals during manufacturing and/or storage. Second, the chemical and 
physical properties of PS80 may change following the formation of trans-FAs. This is concluded 
from a series of studies focusing on FFAs, but also focusing on lipids, synthetic model surfactants, 
or FAs physically incorporated into micelles or inverted micelles, as outlined in the following. 
For example, the critical micelle concentration (cmc) of sodium elaidate (2.5x10-3 M) is slightly 
below that of sodium oleate (2.7x10-3 M), consistent with a greater tendency for association of 
elaidic acid as compared to oleic acid, measured in non-polar solvents46. When the physical 
properties of elaidyltrimethyl ammonium chloride and oleyltrimethyl ammonium chloride 




surfactants led to differences in drag-reduction, micellar structure, and shear viscosities47. 
Likewise, differential scanning calorimetry experiments of lipids show that the cis/trans 
isomerization of 1-palmitoyl-2-oleyl L-α-phosphatidylcholine (POPC) to 1-palmitoyl-2-elaidyl 
L-α-phosphatidylcholine (PEPC) changes the phase transition temperature48. The incorporation 
of increasing concentrations of elaidic acid into inverted micelles generated from monoolein-oleic 
acid reduces the sphericity of these micelles49. Lennox and McClelland studied the chemical 
bromination of elaidic and oleic acid50. They reported that physical incorporation into micelles 
significantly changed the relative reactivities of the cis and trans double bonds as compared to 
bromination in homogenous solution50. 
In conclusion, the light-exposure of a PS80-containing formulation containing a monoclonal 
antibody resulted in the cis/trans isomerization of unsaturated fatty acids (oleic acid, linoleic and 
conjugated linoleic acids). The presence of trans fatty acids may modulate the physico-chemical 
properties of PS80 micelles. In addition, the presence of trans fatty acids may serve as a probe for 
free radical formation and reactions within formulations. It will be interesting to evaluate whether 








§ For photo-irradiations at λmax = 305, 350 and 419 nm, light intensities were integrated over the 
entire emission spectra of the respective lamps, which are available from The Southern New 
England Ultraviolet Company. 
 
$We compared extraction by ethanol, acetonitrile and ethyl acetate/1,4-dioxane (50/50, v/v), and 
found no significant differences in extraction efficiency. 
 
‡We observed that over the lifetime of the column, absolute retention times of the components 
were subject to shift, while the relative elution order remained constant. This is the reason for the 
different retention times in Figures 6A and 6B.   
 
#We note that PS80 (J.T. Baker) originally present in the MedImmune formulation, and PS80 
(J.T. Baker), which we purchased later and spiked into the MedImmune formulation appear to 
vary in the relative content of the three isobaric species prior to photo-irradiation. At this point, 
we do not know whether this is due to batch-to-batch variability or due to the age of the 
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Figure 1: Positive-mode LC-MS chromatograms of PS80 after extraction from the mAbZ 
formulation: Dark control sample (a) and samples photoirradiated (1 h) with λmax = 305 nm (b); 
peak I: POE sorbitan oleic acid, peak IIa: POE oleic acid, peak IIb: isobaric product to IIa; y-axis 




















Figure 2: Figure 2. Positive-mode LC-MS chromatogram of the POE (12) oleic acid ammonium 
adduct (m/z 828.60, z = 1; [M +NH4]+1) after PS80 extraction from the mAbZ formulation: Dark 
control sample (a) and samples photoirradiated (1 h) with λ = 254 nm (b), λmax = 305 nm (c), and 
λmax = 350 nm (d); y-axis scaling: scaling of each subplot is normalized to the maximum signal 




















Figure 3: Negative-mode LC-MS chromatogram of oleic acid (m/z 281.24, [M-H]-1) after FFA 
extraction. PS80 photoirradiated (1 h) with λmax = 305 nm in the absence (a) or presence (b) of 
mAbZ. PS80 in the presence of NATA and GSSG: dark control sample (c) and sample 
photoirradiated (1 h) with λmax = 305 nm (d); y-axis scaling: scaling of each subplot is normalized 












Figure 4: Positive-mode LC-MS chromatogram of the POE (26) sorbitan linoleic acid bis-
ammonium adduct (m/z 803.56, [M +2NH4]+2) after PS80 extraction from the mAbZ formulation: 
Dark control sample (black line) and sample photoirradiated (1 h) with λmax = 305 nm (blue line); 
peaks IIa and IIb: isobaric species of the POE (26) sorbitan linoleic acid ammonium adduct, peaks 
I, III, IV, and V belong to isotopic envelopes of other PS80 species; y-axis scaling: scaling is 


















Figure 5: Negative-mode LC-MS chromatogram of linoleic acid and its isobaric species (m/z 
279.22, [M-H]-1) after FFA extraction from (a) PS80 present in the mAbZ formulation and (b) 
PS80 spiked into the mAbZ formulation (We observed that over the lifetime of the column, 
absolute retention times of the components were subject to shift, whereas the relative elution order 
remained constant. This is the reason for the different retention times in Figures 6a and 6b; We 
note that PS80 (J.T. Baker) originally present in the MedImmune formulation and PS80 (J.T. 
Baker), which we purchased later and spiked into the MedImmune formulation, appear to vary in 
the relative content of the 3 isobaric species before photoirradiation. At this point, we do not know 
whether this is due to batch-to-batch variability or due to the age of the MedImmune 
formulations): Dark control sample (black line) and photoirradiated samples (1 h) with λ = 254 
nm (red line, B only) and λmax = 305 nm (blue line); y-axis scaling: scaling of each subplot is 














Figure 6: Quantitative comparison of linoleic acid and its isobaric species (m/z 279.22, [M-H]-1) 
after FFA extraction from PS80 alone and from PS80 spiked into the mAbZ formulation: Dark 
control samples (black and blue lines, respectively) and photoirradiated samples (1 h) with λmax 
= 305nm (gray and red lines, respectively); ‘9Z, 11E’ refers to (9Z, 11E)-octadeca-9,11-dienoic 




















Figure 7: Negative-mode LC-MS chromatogram of oleic acid oxidation products (m/z 281.24 + 
32, [M-H]-1) after FFA extraction from PS80 present in the mAbZ formulation: Dark control 
sample (a) and samples photoirradiated for 1 h with λ = 254 nm (b), λmax = 305 nm (c), λmax = 350 
nm (d, black line), and for 8 h with λmax = 350nm (d, red line); y-axis scaling: scaling of each 






















Figure 8: Negative-mode LC-MS chromatogram of linoleic acid and its isobaric species (m/z 
279.22, [M-H]-1), and linoleic acid oxidation products (m/z 279.22 + 16 and + 32, both [M-H]-1) 
after FFA extraction from PS80 mixed with NATA and GSSG: Dark control samples (a, c, d, 
black lines) and photoirradiated samples (1 h) with λmax = 305 nm (b, c, d, blue lines); y-axis 



























Figure 9: (a) Raman spectra of FA references in ethanol, (b) Raman spectra of samples after 
biphasic 1,4-dioxane/ethyl acetate extraction, drying, and dissolution in ethanol, (c) Raman 
spectra of PEG and PS80 directly dissolved in ethanol; ‘9Z, 11E’ refers to (9Z, 11E)-octadeca-
9,11-dienoic acid, ‘10E, 12Z’ refers to (10E, 12Z)-octadeca-10,12-dienoic acid, and ‘9E, 11E’ 
refers to (9E, 11E)-octadeca-9,11-dienoic acid; y-axis scaling: scaling of each subplot is 



























Figure 10: (a) FTIR spectra of FA references in ethanol, (b) FTIR spectra of samples after biphasic 
1,4-dioxane/ethyl acetate extraction, drying, and dissolution in ethanol, (c) FTIR spectra of PEG 
and PS80 directly dissolved in ethanol; ‘9Z, 11E’ refers to (9Z, 11E)octadeca-9,11-dienoic acid, 
‘10E, 12Z’ refers to (10E, 12Z)-octadeca-10,12-dienoic acid, and ‘9E, 11E’ refers to (9E, 11E)-
octadeca-9,11-dienoic acid; y-axis scaling: scaling of each subplot is normalized to the maximum 





4.8. Supplementary Figures 
 
Figure S1: Positive mode LC-MS chromatogram of the POE (12) oleic acid ammonium adduct 
(m/z 828.60, [M+NH4]+1) after PS80 extraction from the mAbZ formulation: Dark control sample 
(black line) and sample photo-irradiated (8 h) with λmax = 350 nm (gray line); y-axis scaling: 
scaling is normalized to the maximum signal intensity of the photo-irradiated sample. (For a 







Figure S2: Positive mode LC-MS chromatogram of the POE (26) sorbitan oleic acid bis-
ammonium adduct (m/z 804.56, [M+2NH4]2+) after PS80 extraction from the mAbZ 
formulation: Dark control sample (A) and sample photo-irradiated (1hr) with λmax = 305 nm 







Figure S3: Negative mode LC-MS chromatogram of oleic acid and its isobaric species (m/z 
281.24, [M-H]-1) after FFA extraction from PS80 present in the mAbZ formulation: samples 
photo-irradiated (1hr) with λmax = 305 nm (blue line) and spiked with elaidic acid (red line); y-
axis scaling: scaling is normalized to the maximum signal intensity of the photo-irradiated sample 







Figure S4: Negative mode LC-MS chromatogram of oleic acid and its isobaric species (m/z 
281.24, [M-H]-1) after FFA extraction from PS80 mixed with (A) NATA and GSSG, (B) NATA 
only, and (C) GSSG only; all samples photo-irradiated (1hr) with λmax = 305 nm; y-axis scaling: 






Figure S5: Positive mode LC-MS chromatogram of the POE (12) oleic acid ammonium adduct 
(m/z 828.60, [M+NH4]+1) from PS80 mixed with (A) NATA and GSSG, (B) NATA only, and 
(C) GSSG only; all samples photo-irradiated (1hr) with λmax = 305 nm; y-axis scaling: scaling 





 Chapter 5: Oxidation and Cis/trans Isomerization 
of Unsaturated Fatty Acids in Polysorbate 80 via 





The development of protein therapeutics involves the use of various excipients to keep them stable 
for long shelf lives.1-2 One of the criteria is to maintain the pH of these therapeutics to ensure the 
physical and chemical stability. Therefore, a wide variety of buffers such as citrate, acetate, 
histidine and phosphate buffers are used.3 Citrate is a polyprotic buffer that has four pKa values, 
3.13, 4.75, 5.80, and 14.40,3 and as a result it can buffer over a wide range of pHs. Citrate is 
known to have dual effect on proteins; some studies show that citrate accumulates on protein 
surfaces, leading to reduced colloidal stability,4-9 while others show that citrate can bind to the 
native state of proteins resulting in net stabilization.10-13 For γD-crystalline, citrate buffer in the 
formulation inhibits unfolding and aggregation via ligand binding, and retains the conformational 
stability of the protein.14-15 In addition, degradation products of citrate can react with the N-
terminus or lysine.16-17 For example, citrate-derived products formed covalent adducts of acetone 
and aldimine to a monoclonal antibody that was formulated in citrate buffer in presence of iron 
after light exposure.17  
Although Fe3+ is rather insoluble in water, it becomes soluble through chelation with citrate.18-19 
Depending on the ratio of citrate:Fe3+, pH, temperature, and solvent, a variety of Fe3+-citrate 
complexes may be formed.20 These complexes absorb UV and visible light, eventually generating 
reactive oxygen species (ROS), which can modify the ingredient of formulation.17 Due to the 
generation of ROS, these complexes have also found their use in degrading poorly biodegradable 
pollutants in water under UV-A or sunlight.21-23 Even though drug products may not be exposed 
to sunlight, the fluorescence lamps in the laboratory settings emit UV-A light and visible light,24 
where the Fe3+-citrate complexes absorb. In addition,  trace amounts of Fe3+ are present in 




bioreactors,26-27 glass vials27 and/or rubber stoppers.28 As shown in Scheme 1, reactions 1-4, when 
a citrate-Fe3+ is exposed to the UV-A light, Fe2+ is generated by a ligand-to-metal charge transfer 
(LMCT). Ferrous iron readily reduces oxygen to superoxide (O2•─), which can undergo further 
dismutation to hydrogen peroxide (H2O2).  The combination of Fe2+ and H2O2 promotes the 
Fenton reaction (k4 = 1.10 x 106 M-1s-1) to form •OH,29 which is a strong oxidant that can oxidize 
proteins and surfactants. Therefore, the entire reaction is referred to as photo-Fenton reaction. An 
important aspect of photo-Fenton reaction is the formation of radicals originating from citrate. 
Carboxyl radical (R-COO•) (Scheme 1, reaction 1) are formed from citrate after LMCT and 
transforms into 3-hydroxy-glurate radical (3-HGA•2─) (Scheme 1, reaction 5) after loss of carbon 
dioxide, which in the presence of oxygen converts 3-HGA•2─ to 3-oxo-glutarate (3-OGA2-) 
(Scheme 1, reaction 6).30-31 In terms of R-COO•, it can also degrade to form a carbon dioxide 
radical anion (•CO2─) after multiple steps (Scheme 1, reaction 7).32 This radical anion is a one-
electron reductant that can reduce the disulfide bond forming a thiyl radical and a thiol.33  
Here, we report on the photo-induced oxidation and cis/trans isomerization of polysorbate (PS80) 
by ROS and one-electron reductants such as •CO2─ and 3-HGA•2─, respectively. These radicals 
are generated by photo-irradiation of citrate in the presence of Fe3+, present as a contaminant in 
protein formulations. We have investigated the roles of •CO2─ and 3-HGA•2─ in generating thiyl 
radicals in a model peptide containing a disulfide bond, oxidized glutathione (GSSG), and 
inducing cis/trans isomerization of unsaturated fatty acids of PS80. It is pharmaceutically relevant 
as some of the marketed protein biotherapeutics such as Brentuximab Vedotin (Adcetris), 
Belimumab (Benlysta), Adalimumab (Humira), and Rituximab (Rituxan) are formulated in citrate 




5.2. Materials and Methods 
PS80 N.F. (J.T. Baker) was purchased from Avantor (Radnor, PA). Sodium acetate, phosphate 
monobasic, phosphate dibasic, GSSG, and ferric chloride were purchased from Sigma-Aldrich 
Corporation (St. Louis, MO). Citric acid monohydrate was purchased from Fisher Scientific 
(Hampton, NH). All the solutions were prepared using fresh water of ultra-pure quality (18.2 MΩ) 
using a WaterPro PS Polishing System (Labconco, Kansas City, MO).  
5.2.1. Photo-irradiation 
The solutions were photo-irradiated under air using 4 ml borosilicate glass vials (cut-off of <295 
nm), using four RPR-3500A lamps, emitting wavelengths between 305 nm and  416 nm (λmax = 
350 nm), placed in a Rayonet Photoreactor (RPR-200, The Southern New England Ultraviolet 
Company, Branford, CT). These four lamps gave a photon flux of ~3x10-8 Einstein/s and an 
irradiance of 6.3 W.h/m2 quantified by ferrioxalate actinometer.34-36 Our experimental conditions 
used up to 42 W.h/m2, which is well below the ICH Q1B guideline of the International Conference 
of Harmonization (ICH) recommendation of 200 W.h/m2 of UV-A light for the photo-stability 
testing of drug product and drug substance.37  
5.2.2. Sample preparation 
An initial stock of 10% PS80 (w/v) was prepared and diluted to 0.2% (w/v) in water. Similarly, 
initial stocks of 100 mM buffers (citrate, phosphate and acetate) at pH 6.0, 200 μM Fe3+ and 50 
mM GSSG (pH adjusted to 6.0) were prepared in water. The final desired concentrations of 0.02% 
PS80, 10 mM buffers, 1 μM Fe3+, and 5 mM GSSG were achieved by adding 40 μl of 0.2% PS80, 
40 μl of 100 mM buffer, 2 μl of 200 μM Fe3+, and 40 μl of 50 mM GSSG; the final volume was 




irradiated in borosilicate test tubes under the conditions mentioned above. Some experimental 
conditions required either different concentration of Fe3+ (0-50 μM), different concentration of 
buffers (10-50 mM), or no GSSG. In these cases, the volumes of the solutions were adjusted 
accordingly, and water was added as needed to adjust the final volumes to 400 μl. 
In case of Ar-saturated solutions, the solutions were capped with rubber septa and saturated with 
Ar for 30 min. During Ar-saturation, the solutions were wrapped in an aluminum foil to prevent 
light exposure. After Ar-saturation, the solutions were photo-irradiated as described above. The 
photo-irradiated solutions were stored at -80 °C until further analysis by HPLC-mass 
spectrometry (MS). Control solutions under air or Ar were either wrapped in an aluminum foil 
and placed into the Rayonet Photoreactor during photo-irradiation or were placed in the dark.  
5.2.3. Mass spectrometry 
Control and photo-irradiated solutions were analyzed by HPLC-electrospray MS in the positive 
mode, using a Q-Tof Premier™ (Waters Corporation, Milford, MA) connected to a Waters 
ACQUITY UPLC system (Waters Corporation, Milford, MA). The solutions were introduced 
into the mass analyzer in the ESI source. The desolvation temperature and source temperature 
were maintained at 250 °C and at 120 °C, respectively, and the capillary voltage was set at 2.8 
kV. The mass spectrometer was operated in the MSE mode, collecting fragmentation patterns of 
PS80, which give unique fragmentation ions of fatty acids.38 The analyzed mass range was 150-
2000 Da. The mass spectrometer settings, UPLC settings, and data analysis were achieved with 
the Masslynx v.4.1 software version.  
The resolution of PS80 species and its degradation products was achieved by a Prevail™ C18 




mm particle size. For better separation, the column heater was maintained at 40 °C. Five μl of 
0.02% PS80 was run at the flow rate of 0.4 ml/min. Four mobile phases were employed for the 
separation of the solutions and to clean the column. Mobile phase A contained water, 2 mM 
ammonium formate, and 0.08% formic acid, mobile phase B contained 30% methanol, 70% 
acetonitrile, and 0.08% formic acid, mobile phase C contained 100% isopropanol, and mobile 
phase D contained 10% 1,4-dioxane and 90% acetone. The solvent gradient started with 60% A 
and 40% B, and the organic phase gradually increased linearly to 1% A and 99% B within 15 
min.  The composition was then changed to 1% A, 90% B, and 9% C, and held for 2 min. The 
column was then washed using 1% A and 99% D for 3 min and was re-equilibrated for 7 min 
before the next run.  
5.3. Results 
5.3.1.  Oxidation products  
PS80 is prone to oxidation when exposed to reactive oxygen species, contaminants (such as 
metals and peroxides), heat, and light.39 Here, we monitored the degradation of PS80 in the 
presence of Fe3+-citrate during exposure to UV-A light. MS chromatogram of a control solution 
containing 0.02% PS80 and 10 µM Fe3+ in 10 mM citrate buffer shows PS80 species, which were 
eluted in the following order; at tR = 10.32 min POE sorbitan monolinoleate, at tR = 11.74 min 
POE sorbitan monooleate, at tR = 13.22 min POE oleate, at tR = 17.82 min POE sorbitan oleate-
linoleate, at tR = 18.64 min POE sorbitan dioleate, and at tR = 20.80 min higher order esters were 
eluted. A photo-irradiated solution containing 0.02% PS80 and 10 µM Fe3+ in 10 mM citrate 
buffer (Fig. 1, red trace) was compared with a photo-irradiated solution of 0.02% PS80 in 10 mM 
citrate buffer without Fe3+ (Fig. 2, blue trace) and a control solution. Photo-irradiation in presence 




monolinoleate, at tR = 17.82 min displaying the m/z of POE sorbitan oleate-linoleate, and increase 
of the peak at tR = 13.90 min displaying the m/z of POE oleate with an increase of 30 Da. In 
contrast, photo-irradiation of solutions without Fe3+ did not reveal in significant changes in the 
peak intensities compared to the control sample. These observations suggest the involvement of 
Fe3+-citrate in the degradation of PS80 via a photo-Fenton reaction. The oxidation products of 
PS80 in citrate buffer were quantified after exposure to UV-A light in increased concentration of 
Fe3+ and increased photo-irradiation time shown in section 4.1.1 and 4.1.2, respectively. 
5.3.1.1. Effect of Fe3+ concentration 
The degradation profile of 0.02% PS80 in 10 mM citrate buffer, pH 6.0, was monitored in the 
presence of various concentration of  Fe3+ between 0 and 50 µM Fe3+ (Fig. 2). The peak areas of 
POE (25) sorbitan linoleate (Fig. 2, black trace) display a rapid degradation of this species when 
the PS80 solution in 10 mM citrate buffer contained 5 µM Fe3+ and almost all of this species 
degraded in the solutions containing ≥10 µM Fe3+ after photo-irradiation. POE (25) sorbitan 
monooleate degraded gradually as the Fe3+ concentration increased (Fig. 2, blue trace), indicated 
by its peak areas. Among the PS80 species quantified, POE(11) oleate (Fig. 2, red trace)  
decreased at a slower rate.  
The degradation products of PS80 were monitored by analyzing the peak areas of oxidation 
products, specially of products displaying  an increase of 16 Da, corresponding to the 
addition/insertion of an oxygen atom. These species indicate the formation of hydroxylation 
products (Fig. 3). The oxidation product, POE(11) hydroxy-oleate (m/z = 784.57, z = 1) showed 
gradual increase in peak area when the Fe3+ concentration was increased from 0 to 50 µM Fe3+. 




and POE(25) sorbitan hydroxy-monolinoleate (m/z = 781.54, z = 2) except for the solution 
containing 5 μM Fe3+.   
5.3.1.2. Duration of light exposure 
The solutions containing 0.02% PS80 and 1 µM Fe3+ in 10 mM citrate buffer, pH 6.0, were 
exposed to UV-A light for various time between 0 and 200 min (Fig. 3). As in section 4.1.1, the 
oxidation products were evaluated by extraction of a desired m/z and calculation of relative peak 
areas. The relative peak areas of the oxidation products, such as POE (11) hydroxy-oleate, POE 
(25) sorbitan hydroxy-monooleate, POE (25) sorbitan hydroxy-monolinoleate increased on the 
light exposure extended to 175 min, but did not change further when the solutions were exposed 
for 200 min. A small amount of POE (25) sorbitan hydroxy-monooleate was present in the control 
solution as well.  
5.3.2. Cis/trans isomerization  
5.3.2.1. Cis/trans isomerization of unsaturated fatty acids of PS80 under air 
In presence of Fe3+, a citrate-derived radical is •CO2─ is formed after exposure to UV-A light. 
This radical anion is a reductant and can transfer an electron to a disulfide bond, which 
subsequently breaks the bond forming a thiol and a thiyl radical. Our previous study on cis/trans 
isomerization of unsaturated fatty acids of PS80 was mediated by thiyl radical after an electron 
was transferred to a disulfide bond from a photoionization of tryptophan (Trp).40 Therefore, we 
employed a model peptide containing a disulfide bond, GSSG, to accept an electron from •CO2─, 
reduce to a thiyl radical, and induce cis/trans isomerization of unsaturated fatty acids of PS80. 
Therefore, to confirm this hypothesis, 400 µl of solutions containing 0.02% PS80 (w/v), 10 µM 




A light for 1 h (Fig. 5). Significant changes in the extracted ion chromatogram (XIC) peaks of 
POE(11) oleate and POE(25) sorbitan monooleate were observed for all the light exposed 
solutions in comparison to the control sample that was wrapped in aluminum foil during photo-
irradiation. For photo-irradiated solution containing 10, 20, and 50 mM citrate, the extracted ion 
chromatograms (XICs) of POE(11) oleate, eluting at tR = 13.22 min, with m/z 784.59 (z = 1) (Fig. 
5A), revealed an isobaric peak eluting directly after POE(11) oleate at tR = 13.46 min. The 
obtained isobaric peaks have slight increase in peak areas with increase in buffer concentration. 
Similarly, XICs of POE(25) sorbitan monooleate displaying a molecular ion with m/z 782.52 (z 
= 2) resulted in an unresolved isobaric peak, which was absent in the control sample (Fig. 5B). 
The peak areas of these isobaric species indicated that the increase in citrate buffer concertation 
has very little effect on their formation. This is because 10 mM citrate was already 1000-fold 
higher than 10 µM Fe3+ and all the complexing sites of iron are occupied so increasing the 
concentration further had little effect.  
Next, we investigated the role of increasing concentration of iron on the formation of isobaric 
species. Solutions containing 0.02% PS80 (w/v) and 5 mM GSSG prepared in 10 citrate buffer, 
pH 6.0, with Fe3+ concentration ranging from 0 to 10 µM iron were exposed to UV-A light for 1 
h (Fig. 6). Representatively, XICs of POE(11) oleate displaying a molecular ion with m/z 784.59 
(z = 1) resulted in higher yield of isobaric species in 10 µM Fe3+ compared to 2.5 µM Fe3+ 
containing photo-irradiated sample and control sample (Fig. 6A). Likewise, XICs of POE(25) 
sorbitan monooleate displaying a molecular ion with m/z 782.52 (z = 2) resulted in a new 
unresolved peak, which is absent in both 2.5 µM Fe3+ containing photo-irradiated sample and 




to iron, giving higher yield of •CO2─ that reduces disulfide bonds to thiyl radicals. These thiyl 
radicals then induces cis/trans isomerization of the unsaturated fatty acids of PS80.  
5.3.2.2. Cis/trans isomerization of unsaturated fatty acids of PS80 under Ar 
Since photo-irradiation of citrate-Fe3+ in the UV-A region also generate 3-HGA•2─, a reductant, 
in absence of oxygen, we investigated the role of such radical anion in reducing disulfide bond of 
GSSG and generating thiyl radicals, which can induce cis/trans isomerization of unsaturated fatty 
acids in PS80 under Ar-saturation.  Therefore, Ar-saturated solutions containing 0.02% PS80, 5 
mM GSSG, and 10 µM Fe3+ were prepared in either 10, 20, or 50 mM citrate buffer and exposed 
to UV-A light for 1 h.(Fig. 7). XICs of POE(11) oleate displaying a molecular ion with m/z 784.59 
(z = 1) resulted in an isobaric species, eluting directly after POE(11) oleate, and XICs of POE(25) 
sorbitan monooleate displaying a molecular ion with m/z 782.52 (z = 2) resulted in a new 
unresolved peak, which were observed only in the photo-irradiated samples, and not in control 
sample. Ar-saturated photo-irradiated solution showed a very little effect of increased citrate 
buffer concentration on the yields of these isobaric species. By comparison to the air-saturated 
solution (Fig. 5), in Ar-saturated solution, the yields of isobaric species of both POE(11) oleate 
and POE(25) sorbitan monooleate were lower. Next, concentration of Fe3+ from 0 to 10 µM was 
used in solutions containing 0.02% PS80 and 5 mM GSSG prepared in 10 mM citrate buffer, pH 
6.0, and exposed to UV-A light. XICs of POE(11) oleate with m/z 784.59 (z = 1) resulted in 
isobaric species eluting at tR = 13.46 min in the photo-irradiated samples, but not in the control 
sample. Photo-irradiated solution with 10 µM Fe3+ is in higher yield compared to the photo-
irradiated solution with 2.5 µM Fe3+, which is similar observation made in air-saturated solution; 
however, by comparison Ar-saturated solutions have lower yield of isobaric species of POE(11) 




shoulder peak in  the solution containing 2.5 µM Fe3+ compared to 10 µM Fe3+. Thus, these citrate 
buffer and iron concentration dependent experiments were similar in both air and Ar-saturated 
solutions; however, yields of these isobaric species were higher in air-saturated solution. 
5.3.2.3. Cis/trans isomerization of unsaturated fatty acids in different buffers under Ar 
Apart from citrate, other buffers such as acetate and phosphate are used frequently in the 
biotherapeutic formulations.3 Additionally, disulfides can directly absorb UV light and form thiyl 
radicals, so we investigated the abilities of acetate and phosphate buffers, and disulfide without 
buffers in inducing cis/trans isomerization of unsaturated fatty acids of PS80 via thiyl radicals. 
Hence, Ar-saturated solutions containing 0.02% PS80, 1 µM Fe3+, and 5 mM GSSG that were 
prepared either in no buffer, 10 mM phosphate buffer, 10 mM sodium acetate buffer, or in 10 mM 
citrate buffer at pH 6.0 and were exposed to UV-A light for 1 h. XICs of POE(11) oleate 
displaying a molecular ion with m/z 784.59 (z = 1), showed a small peak, eluting next to all the 
samples, but the yield was higher in citrate buffer. Likewise, XICs of POE(25) sorbitan 
monooleate displaying a molecular ion with m/z 782.52 (z = 2) revealed shoulder peaks in all the 
samples, but citrate buffer had a prominent shoulder peak. These results suggest that disulfide 
bonds without buffers can absorb some UV-A and generate thiyl radicals, which can prompt 
cis/trans isomerization. Since, acetate and phosphate buffers did not increase the yield of isobaric 
species, they suggest little to no effect on cis/trans isomerization. On the other hand, among the 
buffers tested, citrate can form citrate-derived radical ions, which reduce the disulfide bonds to 
thiyl radicals and promote cis/trans isomerization of unsaturated fatty acids of PS80.   
5.4. Discussion 
We observed oxidation of PS80 in solutions containing citrate and Fe3+ after exposure to UV-A 




solutions containing PS80 and Fe3+ in citrate buffer, isobaric species of unsaturated fatty acids of 
PS80 species were observed. Therefore, we hypothesized that the oxidation of PS80 species is 
initiated by the ROS generated during photo-irradiation and the cis/trans isomerization is carried 
out by radical ions, one-electron reductants, which reduce GSSG to give thiyl radicals after one-
electron transfer. These reductants are generated from citrate after LMCT, followed by multiple 
steps discussed in section 5.2 and shown in Scheme 1.  
5.4.1. Oxidation products 
In order to determine the role of ROS in the formation of PS80 oxidation products via the photo-
Fenton reaction, we focused on two experimental conditions (i) different ratios of Fe3+ and citrate 
(Fig. 3) and (ii) duration of light exposure (Fig. 4). Our observations indicate that PS80 oxidation 
depends both on the concentration of Fe3+ and the duration of light exposure. The effect of an 
increasing Fe3+ concentration was most pronounced for oxidation products derived from linoleic 
acid (Fig. 2) suggested by rapid decline of POE(25) sorbitan monolinoleate. Our previous studies 
showed that a large fraction of linoleic acid is in conjugated forms (CLAs).40 In general, we also 
observed an increase in peak areas of the hydroxy products of PS80 species, such as POE(11) 
hydroxy-oleate, POE(25) sorbitan hydroxy-oleate, and POE(25) sorbitan hydroxy-linoleate, as 
we increased the concentration of Fe3+ (Fig. 3) and with longer UV-A light exposure (Fig. 4). The 
formation of ROS such as hydroxyl radical (•OH), a strong oxidant, promotes oxidation of PS80. 
Formation of •OH is dependent on the generation and stability of O2•─, H2O2, and Fe2+ (Scheme 
1, reactions 2-3, 6). The formation of these intermediates depends on the ratio of Fe3+ and citrate 
concentration.  Feng et al. have illustrated that an increase in citrate concentration from 50 µM to 
200 µM with a constant concentration of iron (10 µM) increases the initial rate of •OH formation; 




In our experimental conditions, we have used 10 mM citrate, which is in excess to carry out the 
photo-Fenton reaction. Additionally, in the same study, increasing the concentration of Fe3+ from 
10 µM to 100 µM with constant concentration of citrate (300 µM) showed an increase in the 
initial rate of •OH formation. This result also supports our results as we observed increased PS80 
oxidation product with increasing iron concentration; however, the oxidation product does not 
increase linearly with iron concentration because citrate is a quencher of •OH radical.42 The 
reaction rate of •OH with citrate is 2.4 x 108 M-1s-1 43 and with unsaturated hydrocarbons, such as 
cis-butene, is 3.68 x 1010 M-1s-1,44 suggesting that the unsaturated hydrocarbon fatty acids in PS80 
have higher reactivity with •OH radical. An •OH radical can either abstract a hydrogen atom from 
allylic carbon (dehydrogenation), generating a carbon-centered radical which can readily react 
with oxygen at the diffusion-limited reaction, or it can add to the unsaturated bond forming 
hydroxy radicals (hydroxylation) (Scheme 2).45-47 Such intermediates can lead to peroxy, 
hydroxy, keto, and epoxy product formation.48 The unsaturated fatty acids such as oleic acid and 
linoleic acid were reported as common targets in PS80.39, 48-49 These PS80 oxidation products can 
react with proteins and oxidize labile amino acids such as Met,50-51 affecting the  efficacy of 
proteins.  
5.4.2. Cis/trans isomerization 
Our previous work on PS80 demonstrated the role of thiyl radicals in cis/trans isomerization of 
unsaturated fatty acids of PS80.40 A thiyl radical was generated after an electron transfer from 
photoionized Trp to a disulfide bond after exposure to UV-B light, which was confirmed by using 
a model Trp-containing compound, NATA and GSSG. Namely, we observed increase in the 
concentration of elaidic acid (cis-oleic acid) in MS negative mode. In our present work, we 




UV-A light under air. •CO2─ can react either with H2O2, reduce oxygen, or reduce disulfide bonds. 
•CO2─ reacts with H2O2 at k8 = 7. 3 x 105 M-1s-1 and undergoes a Fenton-like reaction to give •OH 
radical (reaction 8).52  On the other hand, •CO2─ reduces O2 to give O2•─ at k9 = 1 x 109 M-1s-1 
(reaction 9).53 These ROS generated via •CO2─ are also responsible for PS80 oxidation.  
 
 
Instead, in the presence of a disulfide bond, •CO2─  reduces a disulfide bond to an intermediate 
2σ/1σ* three electron bonded disulfide radical anion [RS⸫ SR]─,54 which dissociates into a thiyl 
radical and thiolate within 1 µsec ( reactions 10 and 11).55 A series of studies have indicated that 
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It is noteworthy that in our present study, we also observed isobaric species of unsaturated fatty 
acids of PS80 under Ar (Fig. 7 and 8). Since •CO2─ formation requires O2, it is unlikely that •CO2─ 
is responsible for thiyl radical formation under Ar. Another citrate-derived reductant, 3-HGA•2─, 
readily oxidizes to 3-OGA2─ under air, but may have longer half-life under Ar. As such, 3-HGA•2─ 
can reduce disulfide bond (reaction 13), forming a thiyl radical (reaction 11) and promoting 
cis/trans isomerization. This is suggested by the formation of isobaric species under Ar.  
Our results revealed the formation of isobaric species of PS80 in photo-irradiated solutions 
containing GSSG, which suggested the role of thiyl radicals in cis/trans isomerization of 
unsaturated fatty acids of PS80. Such reactions can also occur in protein biotherapeutics as they 
are commonly formulated in citrate buffer and PS80. Additionally, thiyl radicals can lead to cross-
linking, react with Tyr residue to form tyrosyl radical, and induce free thiol deactivation.33 The 
presence of trans instead of cis fatty acids in surfactants have shown to change the phase transition 
temperature,62 structures of micelles,63-64 drag reduction, and shear viscosities.63 As such, changes 
in micellar structure and other properties of surfactants can reduce its ability to protect proteins 
from aggregation. 
In conclusion, the photo-Fenton reaction resulted in oxidation and cis/trans isomerization of 
unsaturated fatty acids of PS80 species (in the presence of disulfides). The ROS and one-electron 
reductants (•CO2─ and 3-HGA•2─) are generated in the solutions containing citrate and Fe3+after 
exposure to UV-A light. These radical ions can initiate secondary radicals such as thiyl radicals 
in proteins and subsequently generate radical-induced products that can challenge the efficacy 
and safety of the drugs. Further work on the physicochemical properties of  trans fatty acids and  
cis fatty acids will help in understanding their influence on stability of the biotherapeutics. 
3-HGA
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5.6. Charts and Figures 
 



















Figure 1:  MS chromatograms of 0.02% PS80 in 10 mM citrate buffer, pH 6.0; Control: samples 
placed in dark (black trace), photo-irradiated at λmax = 350 nm for 1 h with 0 µM Fe3+ (blue trace) 
and with 10 µM Fe3+ (red trace). For color, refer to the online version.  
 





















Figure 2: Quantification of loss of PS80 species based on relative peak area using LC-MS 
representing POE (25) sorbitan monolinoleate (m/z = 781.57, z = 2) (black trace), POE (25) 
sorbitan oleate (m/z = 782.57, z = 2) (blue trace), and POE (11) monooleate (m/z = 784.59, z = 







































Figure 3: Quantification of PS80 degradation products based on relative peak area using LC-MS 
obtained after photo-irradiation of 0.02% PS80 with increasing concentration of Fe3+ (0-50 µM) 
in 10 mM citrate buffer, pH 6.0, representing (A) POE (11) hydroxy-oleate, (B) POE (25) sorbitan 





















































Figure 4: Quantification of PS80 hydroxylation products based on relative peak area using LC-
MS obtained after photo-irradiation (up to 200 min) of 0.02% PS80 with 1 µM Fe3+ in 10 mM 
citrate buffer, pH 6.0, representing (A) POE (11) hydroxy-oleate, (B) POE (25) sorbitan 










































Figure 5: (A) XIC chromatograms of POE(11) oleate and (B) XIC chromatograms of POE(25) 
sorbitan oleate placed in dark-Control (black trace) and after photo-irradiation of 0.02% PS80 
with 10 µM Fe3+ and 5mM GSSG in 10 mM citrate buffer (blue trace), 20 mM citrate buffer 





























Figure 6: (A) XIC chromatograms of POE(11) oleate and (B) XIC chromatograms of POE(25) 
sorbitan oleate placed in dark-Control (black trace) and after photo-irradiation of 0.02% PS80 
with 5mM GSSG in 10 mM citrate buffer and 1 μM Fe3+ (blue trace), 10 μM Fe3+ (red trace), or 




























Figure 7: (A) XIC chromatograms of POE(11) oleate and (B) XIC chromatograms of POE(25) 
sorbitan oleate placed in dark-Control (black trace) and after photo-irradiation of 0.02% PS80 
with 10 µM Fe3+ and 5mM GSSG in 10 mM citrate buffer (blue trace), 20 mM citrate buffer 






























Figure 8: XIC chromatograms of POE(11) oleate and placed in dark-Control (black trace) and 
after photo-irradiation of 0.02% PS80 with 5mM GSSG in 10 mM citrate buffer and 1 μM Fe3+ 




























Figure 9: (A) XIC chromatograms of POE(11) oleate after photo-irradiation of 0.02% PS80 
with 1 μM Fe3 in GSSG alone (black trace), with GSSG in 10 mM acetate buffer (blue trace), 
with GSSG in 10 mM phosphate buffer (red trace), and with GSSG in 10 mM citrate buffer 













Scheme 1: Generation of carboxyl radical (R-COO•), hydroxyl radical (•OH), 3-hydroxy-glutarate 
radical (3-HGA2-•), 3-oxo-glutarate (3-OGA2-), and carbon dioxide radical anion (•CO2-) via 










































6.1. Summary and conclusions 
The ingredients in drug products are prone to oxidation upon light exposure. Interactions between 
active pharmaceutical ingredients and excipients play a major role in the stability and efficacy of 
the drug products and determine their shelf-lives. It is important to monitor any chemical and 
physical instabilities that may occur during manufacturing, storage, and delivery of these drug 
products. Therefore, the aim of this dissertation is to understand the effect of photo-induced 
radicals and radical ions on physical and chemical instabilities of ingredients in the peptide and 
protein formulations.  
Chapter 2 investigates a role of Met>S•+ on the peptides containing Met-Xn-His sequences, 
which are present in protein biotherapeutics such as mAbs and hPTH. A series of novel 
photoproducts including a covalent cross-link between Met oxidation product(s) and a neighboring 
histidine residue was observed, which is possibly related to a carbon-centered radical generated 
via deprotonation of Met>S•+. A Gly or Gly-Gly bridging Met and His also resulted in the cross-
link product, revealing the possibility of these cross-links formation even when Met and His are 
not linked by an amide bond. These products were identified by HPLC-MS/MS, by reduction with 
NaBH4, derivatization with GRT, and/or alkylation with NEM. The formation of such a cross-link 
may lead to nonreducible aggregates and loss in biological efficacy as it changes the Met residues 
irreversibly.  
Chapter 3 compares the photostability of mAbZ in NaAc and His/Lys buffer when exposed to 
visible light. mAbZ formulated in His/Lys buffer is superior to NaAc buffer as less aggregation 
and color change were observed in His/Lys buffer. A chromophoric photoproduct responsible for 
the color change in mAbZ was characterized by using a model Trp-containing compound, NATA. 




tentative structure of the product was proposed based on 1H-, 13C-, and HSQC NMR spectra. The 
proposed structures have three conjugated rings, which are formed with breakage of an amide 
bond; such products, if formed in CDR region of a mAb, can affect its binding ability and can 
result in a loss of efficacy. Thus, the photo-sensitive proteins should be protected from long 
exposure to visible light in addition to UV light.  
Chapter 4 identified light-induced cis/trans isomerization of unsaturated fatty acids of PS80 (oleic 
and linoleic acid) in the presence of mAbZ under UV-B light. The mechanistic study was carried 
out with NATA and disulfide bonds (GSSG), which indicated the role of thiyl radical in cis/trans 
isomerization. The trans fatty acids, as revealed by negative mode in MS, were confirmed by 
spiking of commercially available free fatty acid standards. The presence of trans fatty acid may 
impact the physicochemical properties of PS80 micelles. Furthermore, together with linoleic acid, 
we detected conjugated linoleic acids in PS80, which also underwent light-induced cis/trans 
isomerization. The conjugated fatty acids are susceptible to radical formation, which can propagate 
other reactions within the formulation.  
Chapter 5 revealed key roles of UV-A light exposed solutions containing citrate and Fe3+ in the 
oxidation and cis/trans isomerization of unsaturated fatty acids of PS80. After generation of light-
induced ROS, oxidation products such as hydroxylation products in PS80 were quantified, which 
increased with increasing iron concentration and longer duration of light exposure. On the other 
hand, citrate-derived one-electron reductants transfer electrons to disulfide bonds (GSSG), leading 
to the formation of thiols and thiyl radicals, which can induce cis/trans isomerization of unsaturated 
fatty acids of PS80, suggested by the formation of isobaric products in oleic acids containing 
species. The presence of trans-fatty acids in modified PS80 may change the structure of PS80 




containing citrate and Fe3+ can also directly react with proteins. Subsequently, these radicals and 
radical ions can generate secondary protein-bound radicals, which can drive unwanted reactions 
and generate oxidation products that can affect their stability and efficacy.  
6.2. Future works 
The formation of photo-induced cross-links in Met-Xn-His sequence (n = 0-2) of model peptides 
is of importance in protein biotherapeutics containing the Met-Xn-His sequence such as mAbs and 
hPTH. Further investigations can be carried out to identify such cross-link between Met oxidation 
product and His in protein biotherapeutics. Changes in the side chain of amino acids can affect 
their function, especially in case of mAb, Met and His play role in receptor binding. Likewise, 
identification of chromophoric species leading to color change in mAbs can give insights into 
degradation of Trp residue, which is one of the important amino acids in CDR region responsible 
for antigen binding.  
Our studies on PS80 degradation suggested that both proteins and other excipients such as citrate 
buffer (with iron) can lead to oxidation and cis/trans isomerization of PS80. Conversion of cis-
unsaturated fatty acids into trans-unsaturated fatty acids may change the micellar structures of 
PS80, so the effect of trans-unsaturated fatty acid on micellar structure and stability of proteins in 
liquid formulation can be carried out.  
 
 
